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Summary 
 
Most of the tumors have a particular energy metabolism strongly relying on glycolysis to 
fulfil their energetic and biosynthetic demands. This observation was first described by Otto 
Warburg in the 1920s, who reported that the metabolic switch from cellular respiration to 
glycolysis takes place even in the presence of oxygen and may be an important event in 
tumorigenesis. Nowadays, this particular phenotype known as the Warburg phenotype is 
considered a hallmark of cancer cells.  
Chromium (Cr) has been used with industrial and commercial purposes, leading to an 
environmental and occupational exposure for many humans. The adverse health effects related to 
Cr-exposure have been identified all over the years and hexavalent chromium [Cr(VI)] is classified 
as a carcinogenic agent to humans, predisposing for lung cancer. However, in spite of extensive 
studies, the mechanisms underlying Cr(VI)-induced carcinogenesis remain essentially unknown. In 
particular, very little is known about the metabolic reprogramming that may be induced by Cr(VI) 
exposure. To further investigate if the metabolic switch is operating in Cr(VI)-induced 
carcinogenesis, BEAS-2B cells were exposed to a single and sub-cytotoxic insult of Cr(VI) and its 
effects in the rates of glycolysis and oxygen consumption, ATP production and in expression levels 
of the glycolytic marker GAPDH and of mitochondrial activity, the catalytic subunit βF1 from the H+-
ATP synthase were determined. Additionally, we assessed the effects of Cr(VI) exposure in the 
production of reactive oxygen species (ROS) and carbonylation of proteins. A single exposure to 
Cr(VI), using a concentration that does not alter the clonogenic potential of cells, decreases the 
oxygen consumption. This change is paralleled by an increase in the glycolytic flux (higher levels of 
lactate production). Moreover, Cr(VI)-treated cells display higher levels of the glycolytic marker 
GAPDH which are correlated with a lower bioenergetic signature (βF1/GAPDH ratio), a metabolic 
parameter previously found to be altered in many types of carcinomas. No alterations in the 
production of ATP are observed after a single exposure to Cr(VI). A short-term exposure to Cr(VI) 
does not induce the production of ROS nor the carbonylation of proteins. 
We have demonstrated that human bronchial epithelial cells treated with a single and 
sub-cytotoxic concentration of Cr(VI) experience a  reprogramming of cellular metabolism. This 
work contributes to our understanding of the metabolic and functional changes underlying 
Cr(VI)-induced lung carcinogenesis. 
 
Key Words: Lung Cancer, BEAS-2B Cells, Cr(VI) Short-term Exposure, Metabolic Shift 
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Resumo 
 
A maioria dos tumores apresenta um metabolismo energético glicolítico de modo a obter 
energia e os requisitos biossintéticos que necessita. Este fénotipo foi inicialmente observado por 
Otto Warburg nos anos 20, que constatou que esta alteração metabólica da respiração celular para 
a glicólise ocorre mesmo na presença de quantidades normais de oxigénio, sugerindo que este 
pode ser um evento importante no processo tumorigénico. Actualmente, este fénotipo particular, 
conhecido como fenótipo de Warburg, é considerado uma característica basilar das células 
cancerígenas.  
O Crómio (Cr) é amplamente utilizado com fins industriais e comerciais, levando a que 
muitos humanos sejam expostos a este metal. Os efeitos ao nível da saúde relacionados com a 
exposição a Cr à muito que foram identificados, sendo o crómio hexavalente [Cr(VI)] classificado 
como um agente carcinogénico para humanos, predispondo para o aparecimento de cancro do 
pulmão. Apesar do número extensivo de estudos, os mecanismos celulares e moleculares 
relacionados com a expoisção a Cr(VI) ainda nao estão totalmente desvendados. Em particular, 
pouco é sabido sobre a reprogramação metabólica que poderá ocorrer. De modo a investigar se 
alterações metabólicas ocorrem durante a carcinogénese induzida por Cr(VI), células BEAS-2B 
foram expostas a um único insulto sub-citotóxico de Cr(VI) e os seus efeitos ao nível do fluxo 
glicolítico, produção de ATP e níveis de expressão dos marcadores de glicólise, GAPDH, e de 
actividade mitocondrial, subunidade catalítica βF1 da H+-ATP sintase, foram determinados. 
Adicionalmente, testámos os efeitos da exposição a Cr(VI) na produção de espécies reactivas de 
oxigénio e na carbonilação de proteínas celulares. Uma exposição única a Cr(VI), usando uma 
concentração que não afecta o potencial clonogénico das células, leva a uma diminuição do 
consumo de oxigénio. Esta alteração ocorre paralelamente com o aumento do fluxo glicolítico 
(maiores níveis de produção de lactato). Além disso, células tratadas com Cr(VI) têm um maior nível 
de expressão do marcador glicolítico, o que se correlaciona com uma menor assinatura 
bioenergética (razão βF1/GAPDH). Não são observadas alterações na produção de ATP após 
tratamento único com Cr(VI). Um único insulto de Cr(VI) não induz a produção de espécies 
reactivas de oxigénio nem a produção de proteinas celulares carboniladas.  
Com este trabalho demonstrámos que células epiteliais humanas de pulmão expostas a um 
único tratamento sub-citotóxico com Cr(VI), sofrem uma reprogramação do seu metabolismo 
energético, o que contribui para o nosso conhecimento das alterações metabólicas e funcionais 
que ocorrem no desenvolvimento de cancro de pulmão.        
 
 
Palavras-chave: Cancro do Pulmão, Células BEAS-2B, Exposição curta a Cr(VI), Alteração Metabólica 
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1.1) The Metabolism of Glucose in Mammalian Cells 
 
In most normal mammalian cells glucose is the preferred metabolic substrate for the 
generation of energy and building blocks required for maintenance, accretion and/or 
proliferation. The extraction of energy from glucose can occur by two general processes: 
glycolysis (with lactate production) and cellular aerobic respiration (Fig. 1.1), the latter 
comprising three major pathways: glycolysis, tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation (OXPHOS) - and allowing the complete oxidation of glucose. These pathways 
take place in the cytosol (glycolysis) and in mitochondria (TCA cycle and OXPHOS). In anaerobic 
glycolysis, glucose is not completely oxidized and lactate is formed (see below) [1,2]. 
During glycolysis (Fig. 1.1), a molecule of glucose is partially oxidized yielding two 
molecules of pyruvate. Some of the free energy released from the hexose is conserved in two 
molecules of adenosine triphosphate (ATP) and two molecules of reduced nicotinamide 
adenine dinucleotide (NADH) [1,2]. The glycolytic flux is strictly regulated by several 
mechanisms in order to maintain constant the levels of ATP. These mechanisms involve a 
complex interaction between ATP consumption, NADH regeneration, allosteric regulation of 
several glycolytic enzymes and the levels of key metabolites. Among the glycolytic enzymes, 
some such as hexokinase (HK, EC 2.7.1.1), 6-phosphofructo-1-kinase (EC 2.7.1.11) and pyruvate 
kinase (EC 2.7.1.40) are strictly regulated. The key metabolites for the regulation of glycolysis 
are fructose 2,6-bisphosphate and cyclic adenosine monophosphate (cAMP) that reflects the 
cellular balance between ATP production and consumption. Moreover, glycolysis is also 
regulated by the hormones glucagon, epinephrine and insulin, and by changes in the 
expression levels of the genes encoding several glycolytic enzymes [2].  
When cells have a limited supply of oxygen, glycolytic pyruvate is reduced to lactate 
promoting the regeneration of oxidized nicotinamide adenine dinucleotide (NAD+) from NADH. 
This reaction is catalyzed by lactate dehydrogenase (LDH, EC 1.1.1.27) and the excess of lactate 
is excreted by the cell [1,2].  
However, under aerobic conditions mammalian cells oxidize pyruvate to CO2 by the 
sequential activity of pyruvate dehydrogenase (PDH, EC 1.2.4.1) and of the TCA cycle, forming 
ATP and the reduced coenzymes NADH and flavin adenine dinucleotide (FADH2) [1,2]. In the 
mitochondrial inner membrane, there is a chain of electron-carrier compounds, known as 
respiratory chain that drives electrons from the reduced coenzymes to molecular oxygen, 
which acts as the terminal electron acceptor. The energy of the electron transfer is efficiently 
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conserved in a proton gradient, resulting from the proton pumping from the mitochondrial 
matrix to the inter-membrane space through the proteic complexes. The electron-carrier chain 
is constituted by four (I to IV) protein complexes. For each pair of electrons transferred to O2 
from NADH, four protons are pumped out of the mitochondrial matrix by complex I, four by 
complex III and two by complex IV [1,2]. With FADH2 as the electron donor, the electron-
carrier complexes pump a total of six protons. The electrochemical energy inherent to this 
difference in proton concentration and separation of charge represents a temporary 
conservation of much of the energy of electron transfer. The energy stored in such a gradient 
is termed the proton-motive force. The re-entry of protons into the mitochondrial matrix 
through the H+-channel of the mitochondrial H+-ATP synthase (EC 3.6.1.34) drives the synthesis 
of ATP in OXPHOS [1, 2]. The terminal oxidation of pyruvate in mitochondria yields almost 20-
fold more ATP than glycolysis. On the other hand, glycolysis can occur in the absence of 
oxygen, being a quick process that occurs a hundred times faster than cellular respiration [1-3].   
The use of glucose by the cell is not restricted to its oxidation for ATP generation. 
Another possible fate of glucose is to be catabolised in the pentose phosphate pathway (PPP) 
to obtain reducing power in the form of reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) and biosynthetic intermediates that can be used in different anabolic processes (Fig. 
1.1), such as lipogenesis. Noteworthy, ribose 5-phosphate necessary for nucleic acid synthesis, 
and NADPH, the principal reducing power in many biosynthetic reactions, are both provided by 
the PPP. Even when glucose is converted to pyruvate and this molecule is partially oxidized in 
the TCA cycle, some of the TCA intermediates could be used for biosynthetic purposes. For 
instance, oxaloacetate and α-ketoglutarate, both intermediates of TCA cycle, are precursors of 
aspartate and glutamate, respectively, which can be used for synthesis of other amino acids, 
purines and pyrimidines. Citrate is a precursor of fatty acids and steroids. The usage of TCA 
cycle intermediates for biosynthetic purposes drives anaplerotic reactions to re-establish their 
levels and ensure the maintenance of the correct flux. Glutaminolysis provides oxaloacetate 
through glutamine catabolism. Also, the conversion of glutamine to lactate generates reducing 
power in the form of NADPH.   
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Fig. 1.1- Pathways of glucose metabolism. The model shows some of the relevant aspects of the 
metabolism of glucose. After entering the cell by specific transporters, glucose is partially oxidized in 
glycolysis to generate energy, reduced power and pyruvate. In the cytosol, the generated pyruvate can 
be reduced to lactate and excreted by the cell or oxidized in the mitochondria by pyruvate 
dehydrogenase to generate acetyl CoA, which enters in the TCA cycle. The operation of the TCA cycle 
completes the oxidation of acetyl CoA. The transfer of electrons obtained in biological oxidations 
(transported by NADH/FADH2) to molecular oxygen by respiratory complexes of the inner mitochondrial 
membrane (in green) is depicted by yellow lines. The utilization of the proton gradient generated by 
respiration for the synthesis of ATP by the ATP synthase (in orange) in OXPHOS is also indicated. Glucose 
can also be catabolized by the PPP to obtain reducing power in the form of NADPH, be used for the 
synthesis of other carbohydrates or utilized to generate other metabolic intermediates that could be 
used in different anabolic processes (blue boxes). Different pathways that drain intermediates of the 
TCA cycle (oxaloacetate, succinil-CoA, α-ketoglutarate and citrate) for biosynthetic purposes are 
represented (blue boxes). Abbreviations: PPP, pentose phosphate pathway; NADPH, reduced 
nicotinamide adenine dinucleotide phosphate; acetyl CoA, acetyl coenzyme A; TCA, tricarboxylic acid; 
NADH/NAD+ reduced/oxidized nicotinamide adenine dinucleotide; ATP, adenosine triphosphate; 
FADH2/FAD, reduced/oxidized flavin adenine dinucleotide; OXPHOS, oxidative phosphorylation [4].  
 
1.1.1) Role of Mitochondria in Cellular Physiology 
Mitochondria are membrane-enclosed organelles, a few micrometers long, found in 
most eukaryotic cells. The number of mitochondria in a cell varies widely by organism and 
tissue type. This organelle is compartmentalized, and specialized functions occur in its 
different regions. These compartments or regions include the outer membrane, the 
intermembrane space, the inner membrane and the matrix. The outer membrane has a high 
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permeability to small molecules and ions, whereas the inner membrane is practically 
impermeable to all polar molecules and ions, including protons. The inner mitochondrial 
membrane includes, among other components, the respiratory electron carriers (complexes I 
to IV), the adenine nucleotide translocase and the H+-ATP synthase (complex V). The 
mitochondrial matrix contains the PDH complex and the enzymes of the TCA cycle, amino acid 
oxidation and -oxidation pathways. In the matrix is also found deoxyribonucleic acid (DNA), 
ribosomes, few ions (Mg2+, Ca2+, K+), and many other enzymes and metabolic intermediates [2]. 
Some of the protein constituents of the respiratory chain are codified by DNA contained 
in mitochondria (mtDNA). However, only 13 polypeptides necessary for mitochondria are 
actually coded by mtDNA and the greater part of them are nuclear-encoded. Though, all 
OXPHOS complexes, with the exception of complex II, contain at least one polypeptide codified 
by the mtDNA. [5,6].  
The H+-ATP synthase is an F-type ATPase that contains two different subcomplexes. The 
F1-ATPase sub-complex contains the subunit β-F1-ATPase (βF1), which protrudes into the 
matrix of the mitochondria and has the catalytic activity necessary for the synthesis of ATP. 
The Fo sub-complex, which is integral to the membrane and acts as a proton channel, allows 
the re-entry of H+ to the mitochondria matrix for the synthesis of ATP [2]. 
The function of mitochondria in the cell is not limited to the production of ATP. They 
play essential roles in the execution of cell death and in intracellular signalling of calcium and 
reactive oxygen species (ROS). Importantly, these different processes are interconnected. The 
production of ROS and the activation of the mitochondrial-dependent cell death pathway are 
linked to the energy metabolism. The maintenance of the mitochondrial membrane potential 
(Δψm) within certain limits is very important, because when Δψm increases the formation of 
ROS augments exponentially [7]. In non-glycolytic cells treated with an apoptosis inducer, H+-
ATP synthase activity supports high Δψm and the subsequent generation of ROS. The formation 
of ROS, controlled by the activity of H+-ATP synthase, is a death signal required for efficient 
execution of programmed cell death. Apoptosis is initiated by release of ROS-modified 
apoptogenic molecules from mitochondria [8].  
Therefore, a growing number of human diseases are now associated with molecular 
and/or functional alterations in mitochondria.  
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1.2) Cancer, Metabolism and Mitochondria 
 
Cancer is considered a complex genetic disease that confers to cells three general 
properties: unlimited replicative potential, metastasis and colonization of different tissues. The 
transformation of normal cells into progressive malignancy is a multistep and sequentially 
ordered process. In addition to the contribution of genetic mutations in cancer genes, the 
progression of cancer is also bound to the cancer cell environment and to other epigenetic 
events [5]. 
In this regard, Hanahan and Weinberg in 2000 identified six general traits of the cancer 
cell: self-sufficiency in growth signals, insensitivity to anti-growth signals, limitless replicative 
potential, evasion of apoptosis, sustained angiogenesis and tissue invasion and metastasis [9]. 
In the ensuing decade, carcinogenicity studies showed that the carcinogenic process is much 
more complex and involves modifications in other cellular properties. As a consequence, 
Hanahan and Weineberg, in 2011, have proposed the addition of two emerging hallmarks (Fig. 
1.2), namely the deregulation of cellular energetics and the avoidance of immune destruction. 
They have also proposed two cellular modifications that enable the acquisition of these eight 
hallmarks during carcinogenesis: cells with altered genotypes will have a selective advantage 
to grow in a specific tissue environment and virtually all neoplasias are infiltrated in different 
degrees with immune system cells [10] (Fig. 1.2). 
Fig. 1.2- The hallmarks and enabling characteristics of cancer cells. The properties identified by 
Hanahan and Weinberg altered in cancer cells are schematically represented. They proposed the 
existence of eight modifications acquired during the process of tumorigenesis by cells. Underlying the 
hallmarks are two enabling characteristics, genome instability and tumor-promoting inflammation. 
Adapted from [10].  
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1.2.1) An Emerging Hallmark: Metabolic Reprogramming 
One of the recently proposed emerging hallmark of cancer, the so called “metabolic 
reprogramming” [11,12] was, in fact, partially described by Otto Warburg almost a century 
ago. The German scientist observed that tumors have an abnormally high aerobic glycolysis 
and suggested that the bioenergetic activity of mitochondria was impaired in the cancer cell 
[13,14].  
In the 1920s, Otto Warburg first reported that, even in the presence of oxygen, tumor 
cells consume larger amounts of glucose and produce higher amounts of lactate than their 
normal counterparts [13,14]. The phenomenon became known as the Warburg effect. 
In his extensive metabolic experiments, Warburg measured the amount of oxygen 
consumed by tumor slices and mouse ascites cancer cells (which he considered almost pure 
cultures of cancer cells) and correlated the values obtained to the quantity of ATP produced by 
cellular respiration or by glycolysis. Surprisingly, he found that cancer cells obtained almost the 
same amount of energy from glycolysis as from respiration, whereas non-malignant cells 
produced most of their energy by respiration. Warburg ascribed this observation to an 
impairment of the bioenergetic function of mitochondria in cancer cells, suggesting that this 
metabolic change is the determinant event in tumorigenesis [13]. 
Warburg’s hypothesis was considered by many authors as a simple Pasteur Effect, which 
settled that oxygen availability controls the rate of glucose utilization by the cells [15-17]. 
Warburg’s postulates were debated for many years, and finally considered an irrelevant 
epiphenomena of cell transformation, until their recent rediscovery mostly propitiated by the 
use of  2-[18f]fluoro-2-deoxyglucose - positron emission tomography imaging in oncology [18]. 
 
1.2.2) Mechanisms Underlying the Warburg Effect 
Cancer cells demand higher levels of energy and biosynthetic precursors, due to their 
fast proliferating characteristics. Their stronger reliance on glycolysis to fulfil these demands 
causes them to consume more glucose and produce more lactate [19]. Diverse mechanisms 
have been proposed to explain the metabolic switch from mitochondrial respiration to aerobic 
glycolysis experienced by tumor cells.  
Due to higher rates of proliferation, a hypoxic microenvironment can be created within 
cancer cells. Hypoxia results in the stabilization of the hypoxia-inducible transcription factor 
(HIF-1). HIF-1 is constituted by two subunits: HIF-1, expressed constitutively, and HIF-1, 
whose levels are dependent on the oxygen pressure in tissues and/or on the activation of 
specific growth factors. Thus, the formation of HIF-1 complex is mainly regulated by HIF-1 
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levels [3,20,21]. Under normoxia, the -subunit is rapidly degraded by the ubiquitin-
proteasome system. The degradation of HIF-1 depends on the activation of HIF-prolyl 
hydroxylases (PHD, EC 1.14.11.2) and the von Hippel-Lindau (VHL) protein that allows the 
degradation by 26S-proteasome [3,20,21]. The lack of VHL allows the stabilization of HIF-1α 
even in normoxia, because the proteasome-dependent degradation is blocked [22]. The 
stabilization of HIF-1 induces the expression of the glucose transporter 1 (GLUT-1) and many 
glycolytic enzymes, such as aldolase (EC 4.1.2.13) and enolase (EC 4.2.1.11), LDH and the 
glycolytic regulator 6-phosphofructo-2-kinase (PFK-2)/fructose-2,6-biphosphatase, as well as 
the factors that trigger angiogenesis (vascular endothelial growth factor, VEGF), cell growth 
and survival pathways (insulin-like growth factor 2, IGF2) [23-25]. HIF-1 also regulates the 
activity of complex IV by stimulating the expression of cytochrome c oxidase (COX) subunit 2 
(COX4-2), instead of COX4-1. This variation of isoforms leads to an optimization of the 
efficiency of OXPHOS by increasing complex IV activity, when O2 is a limiting factor. The higher 
efficiency of COX4-2 enables an attenuation of ROS production [26]. It has also been suggested 
that the glycolytic phenotype can be promoted through cooperation of HIF-1 with the 
oncogene c-Myc (when this one is over-expressed) by induction of pyruvate dehydrogenase 
kinase isoform 1 (PDK-1), hexokinase isoform 2 (HK-2) and LDHA [27]. PDK-1 phosphorylates 
and inactivates the PDH complex, inhibiting the mitochondrial metabolism of pyruvate. 
Frequently, tumors overproduce HK-2, which neutralizes the capacity of glucose 6-phosphate 
to inhibit glycolysis [28]. The high levels of glucose 6-phosphate can also stimulate the PPP that 
provides intermediates for biosynthesis and leads to increased levels of the coenzyme NADPH. 
Importantly, the formation of NADPH leads to an accumulation of reduced glutathione (GSH) 
that acts as a ROS scavenger, thus supporting cell survival [28-31]. In renal carcinoma cells 
lacking the VHL protein, the biogenesis of mitochondria can be indirectly repressed by gain-of-
function of HIF-1α. HIF-1 mediates this effect again by interacting with c-Myc [32]. Overall, the 
activation of HIF-1 complex results in the stimulation of the glycolytic flux and attenuation in 
the mitochondrial activity [27].  
Oncogenes per se can also activate glycolysis. Activation of the Akt and Ras oncogenes 
results in increased glucose transport and stimulation of HK-2 and PFK-2 activity, which 
enhances glycolytic rates [3,33]. There are evidences that Myc oncogene activates glycolytic 
genes and mitochondrial biogenesis, which when sustained by high Myc levels can result in 
ROS production [3,33]. The oncogene Akt seems to promote cell survival by a glucose 
hydrolysis-dependent mechanism after growth factor withdrawal [34]. In addition, Akt 
stimulates the oxidation of glucose, which correlates with tumor aggressiveness in vivo [35]. In 
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non-invasive radial growth melanomas, the over-expression of Akt induces the expression of 
glycolytic markers, as well as a shift to malignant and invasive vertical-growth phenotype [36]. 
The increased glucose uptake mediated by Akt stimulates the formation of NADPH in PPP, 
which is necessary for de novo lipogenesis [37].      
The tumor suppressor protein p53 is also important in promoting the metabolic shift 
from mitochondrial processes to glycolysis. Besides its role in cell cycle control, p53 has an 
important function in the control of the metabolic status of the cell. In normal conditions, p53 
leads to stimulation of cellular respiration, because it stimulates the expression of COX2 
protein that is necessary for the assembly of COX complex [38]. Moreover, p53 acts as a 
negative regulator of glycolysis under glucose deprivation, because it can induce cell cycle 
arrest until fuel restoration [39]. In several types of cancer cells, p53 functions are more or less 
lost, causing the suppression of OXPHOS and glycolysis up-regulation [39, 40].  
Mutations in mitochondrial genes codified by mtDNA are also associated with 
tumorigenesis. These mutations can diminish complexes I and III activities and increase ROS 
production [41]. mtDNA has characteristics that make it an easy target for genetic damage, like 
the location nearby ROS generation sites, lack of protection by histones and a weak capacity of 
DNA repair in the mitochondria. In fact, mtDNA mutations have been observed in leukemia, 
prostate, gastric and breast cancers [42]. Experiments with cells devoid of mtDNA (rho0 cells) 
provide evidences that mtDNA can be important in the process of malignant transformation. 
Rho0 cells derived from breast tumors and glioblastomas lost some of their tumorigenic 
characteristics when the mtDNA was removed and the same malignant features were restored 
upon introduction of normal DNA-containing mitochondria. Rho0 HeLa cells cannot form 
tumors when injected into nude mice, but this capability is restored upon introduction of 
mtDNA from normal human fibroblasts [43]. Moreover, mutations in nuclear-encoded 
mitochondrial genes are also found in some types of cancers. Mutations in the codifying genes 
of succinate dehydrogenase (SDH, EC 1.3.5.1), a TCA cycle enzyme, cause the accumulation of 
succinate, which in turn inhibits PHD and HIF-1α degradation. Inherited or somatic mutations 
in SDH codifying genes are associated with the development of phaeochromocytoma and 
paraganglioma [44,45]. 
The over-expression and/or downregulation of the above-mentioned genes cannot be 
the only events responsible for the development and sustenance of a glycolytic phenotype, 
since the metabolic reprogramming is found in the most prevalent types of cancers and the 
frequency of mutations in these genes is lower [4]. So, the progression of malignancy may also 
be triggered by non-mutational events. In this regard, plausible modifications that may be 
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linked to the metabolic reprogramming are the structural and functional impairments of 
mitochondria, since many metabolic and bioenergetic functions take place in this organelle 
[4,46].  
Indeed, a proteomic approach used to determine the expression of both glycolytic and 
mitochondrial proteins has revealed an altered pattern in tumors. This approach allows protein 
estimation of both bioenergetic competence of the organelle (as assessed by the ratio 
between two mitochondrial proteins, F1 and heat shock protein 60 (Hsp60)) and overall 
mitochondrial potential of the cell (as assessed by the ratio between F1 and the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH)). The latter ratio is defined as 
the Bioenergetic Cellular (BEC) Index or bioenergetic signature of the cell [46,47]. The analysis 
of these two ratios in tumors when compared with normal tissues gives information about 
possible interferences with mitochondrial activities of the cell [4,47]. Several studies have 
demonstrated a reduction of the bioenergetic competence of mitochondria and an up-
regulation of glycolytic flux in many human carcinomas, such as breast adenocarcinomas, 
gastric adenocarcinomas and squamous carcinomas of the lung [12,48,49]. The bioenergetic 
signature inversely correlates with the increase of the glycolytic flux, suggesting a relationship 
between these two parameters in cancer cells [12]. Moreover, the bioenergetic signature 
could be used as a marker for progression of different types of cancer [47,50,51]. 
 
 
1.3) Chromium 
 
For many years, chromium (Cr) has been used with industrial and commercial purposes, 
leading to an environmental and occupational exposure for many humans. The adverse health 
effects related to Cr exposure have also been identified all over these years, especially at the 
level of the skin and respiratory tract. In particular, the multiple epidemiological studies and 
the results from in vitro and in vivo experiments led the International Agency for Research on 
Cancer (IARC) to classify hexavalent chromium [Cr(VI)] compounds, as encountered in the 
diverse Cr-related industries, as a carcinogenic agent to humans (group 1) [52]. The collected 
data revealed a consistent association between exposure to Cr(VI)-containing compounds and 
an increased risk for lung cancer. However, despite many extensive studies, the mechanisms 
underlying Cr(VI)-induced carcinogenesis remain essentially unknown. Therefore, the effects 
exerted by Cr(VI) at the intracellular level, must be dissected in order to better understand the 
complexity of Cr(VI)-induced carcinogenesis.  
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1.3.1) Chemical Properties  
Cr is a chemical element that belongs to group 6 and to the 4th period of the Periodic 
Table and has the configuration [Ar]3d54s1. Although the oxidation states of chromium range 
from -II to +VI [53], the only valence states that occur naturally in the environment are the 
trivalent [Cr(III)] and the hexavalent [Cr(VI)] states, being the latter primarily produced by 
anthropogenic sources [54,55]. Cr(III) complexes are characterized by a low spin, octahedral 
geometry. The majority of Cr(III) complexes are kinetically inert [56]. Cr(VI) is a powerful 
oxidizing agent. The two forms present in aqueous solution are chromate (CrO4
2-) and 
dichromate (CrO7
2-). Therefore, Cr(VI) exists always as an oxyanion in aqueous solution [55]. 
Both chromate and dichromate have a tetrahedral structure, but they have different 
reactivities, being the latter a stronger oxidizing agent [57].    
 
1.3.2) Industrial Applications 
Cr is widely used in metallurgical, refractory and chemical industries. In the metallurgical 
industry, Cr is mostly used to produce ferrous and non-ferrous alloys and stainless steel 
materials [53]. The stainless steel industry uses a mixture of different metals to produce a 
component used during the welding processes. These materials contain up to 30% of Cr, in 
both the trivalent and hexavalent states [58]. In the refractory industry, Cr is used to produce 
heat-resistant materials, such as firebricks for fumaces, since Cr has a high melting point and 
resists to acid and alkali damage [53]. In the chemical industries, both Cr(III) and Cr(VI) are 
used mainly as pigments. For instance, the two forms of Cr(VI) in solution are colourful, being 
yellow (chromate) or orange (dichromate). Other uses for Cr compounds include Cr(VI) in 
metal finishing, Cr(III) in leather tanning, and Cr(VI) in wood preservatives [59].  
 
1.3.3) Exposure to Cr and its Physiological Relevance  
Cr can be found in air, soil and water due to the manufacture and disposal of chromium-
based products. Also, Cr can be found on tobacco smoke. The concentration of Cr in rural and 
urban areas is generally low (<10 ng/m3 in rural areas and 0-30 ng/m3 in urban areas) but, for 
instance, as a result of smoking the concentration of indoor air contaminated with Cr can be 
10-400 times higher [59].  
Cr has been identified in the tissues of occupationally-exposed humans and the principal 
route for the absorption of Cr seems to be the lungs, which depends on the oxidation state, 
size and solubility of the Cr particles [60,61].  
Trivalent compounds normally have low toxicity, being poorly absorbed by the lungs and 
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gastrointestinal tract [53,54]. In fact, Cr(III) seems to have an important role in insulin 
metabolism of patients with diabetes, being used as a nutritional supplement [62]. 
Cr(VI) particles are retained in lung tissue, specially at bronchial bifurcations, where they 
can persist for twenty years and cause airway hypersensitivity, respiratory distress, 
fibroproliferative disease and, ultimately, pulmonary carcinogenesis [63]. The Cr(VI) particles 
that pose the major oncogenic risk are the ones raging from 0.2 to 10 μm, resulting from 
industrial activities [64]. Fortunately, Cr(VI) present in these particles can be inactivated by 
mammalian defence mechanisms. This inactivation is done extracellularly by reduction of 
Cr(VI) to Cr(III). In particular, De Flora et al (1997) have demonstrated that whole blood, lung 
epithelial fluid, alveolar macrophages, and peripheral parenchyma cells have the ability to 
reduce Cr(VI) to Cr(III) [65]. Systemic Cr(III) does not appear to be stored for extended periods 
of time within the body tissues [59]. 
The potential carcinogenic effect of Cr(VI) enters in discussion when it is actively 
transported to the cells before being reduced. At physiological pH, the predominant form of 
Cr(VI) is the chromate oxyanion with a tetrahedral structure similar to those of sulfate and the 
phosphate oxyanions. Therefore, it is non-specifically transported and accumulated by cells 
[66,67]. On the contrary, Cr(III) forms low-spin, octahedral coordination complexes and 
chelates, which are very large compounds that cannot easily be transported through the cell 
membrane [63]. This structural aspect may be one of the causes for the fact that no adverse 
effects were observed in workers exposed to Cr(III) compounds for up to 25 years, whilst 
chronic exposure to Cr(VI)-containing compounds was shown to be associated with an 
increased risk for lung cancer [18-21]. Another possible factor for the greater toxic potency of 
Cr(VI) relative to Cr(III) is the higher redox potential of Cr(VI). Cr(VI) is rapidly reduced to Cr(III), 
with Cr(V) and Cr(IV) species as intermediates [68]. These intermediates, as well as Cr(VI) can 
be involved in the oxidative damage of many cellular constituents (discussed in the subsequent 
sections).  
The most prevalent type of lung cancer reported among Cr(VI) workers is squamous cell 
carcinoma, a sub-type of non-small cell lung cancer [63,69,70]. Nonetheless, small cell 
carcinoma was reported as the type usually detected in Slovakia [71].      
 
1.3.4) Intracellular Metabolism of Cr(VI) 
In the hexavalent state, Cr has little relevant biological activity, i.e., has a reduced 
interaction with macromolecules [54]. Inside the cell, and at different sites (cytosol, 
mitochondria, nucleus and endoplasmatic reticulum), the hexavalent ion is readily reduced to 
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Cr(III). The non-enzymatic reduction is performed mainly by ascorbate (Asc), GSH and cysteine 
(Cys) [54]. Of these, Asc seems to be the primary reducer agent, since it has a high 
intracellular concentration (in the milimollar range) and has a faster reduction kinetics, 
when compared with GSH or Cys [72].  Other cellular constituents can potentially reduce Cr(VI) 
to Cr(III), such as hydrogen peroxide, diols, α-hydroxycarboxylic acids, among others [63].  
Intracellularly, there are two mechanisms for Cr(VI) reduction. The first one occurs at 
relatively low levels of Asc, where a series of one electron reduction reactions take place, 
producing the intermediates Cr(V) and Cr(IV) and, ultimately, Cr(III) (equation 1.1). When the 
amount of intracellular reductants is not limiting, Cr(VI) is directly reduced to Cr(IV) followed 
by a one electron reduction to Cr(III) [73, 74] (equation 1.2).  
 
 
 
 
GSH and Cys can also reduce Cr(VI) by both pathways [54]. Moreover, in the case of Cys, 
kinetic studies at neutral pH showed that major route to reduce Cr(VI) is the one-electron 
transfer [75]. In vivo, the formation of one or two Cr intermediates depends not only on the 
proportion reducer:Cr(VI), but also on additional specifications, like the presence of other 
oxidants and catalytic metals such as Fe [76-78]. 
 
1.3.5) Proposed Mechanisms for Cr(VI) Intracellular Toxicity  
The carcinogenic potential of Cr(VI)-containing compounds is very complex and many 
mechanisms have been proposed. Taking into account that cancer is generally viewed as a 
genetic disease, many researchers conducted their studies in order to clarify the genotoxic 
effects of Cr compounds. Cr(VI) does not interact or bind directly with nucleic acids, but its 
reduction intermediates, and ultimately Cr(III) have a high affinity for DNA, as well as for 
proteins. [54].  
Cr(III) has six coordination sites and, consequently, can form several types of complexes 
with biomolecules. Ternary DNA-crosslinks with other molecules (GSH, Cys, histidine and Asc) 
represent the major Cr-DNA adducts present in mammalian cells [79]. In addition, other types 
of structures can be formed: Cr(III)-DNA binary complexes, DNA-protein crosslinks and DNA 
inter/intrastrand crosslinks. Single- and double-strand breaks and abasic sites are also 
observed upon Cr(VI) exposure [54,63]. However, not all adducts appear to have the same 
mutagenic and, concomitant carcinogenic potential. Under physiological conditions, the Asc-
Cr6+ Cr5+ Cr4+ Cr3+ 
Cr6+ Cr4+ Cr3+ 
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Cr(III)-DNA cross-links seem to be the most mutagenic lesions (Fig. 1.3) [79].   
It has also been proposed that oxidative damage has a major role in Cr-induced toxicity. 
Several theories proposed that this toxicity is achieved trough Cr intermediate oxidation states 
(Cr(V) and Cr(VI)). The damage can be induced by direct electron abstraction by Cr species [77], 
formation of ROS [76] or via Cr(V)-peroxo-intermediate formation [78]. Several studies have 
shown the participation of Cr(VI), Cr(V) and Cr(IV) in Fenton-like reactions (equation 1.3), 
producing hydroxyl radicals, in which Cr(V) is continuously recycled into Cr(VI) [80].  
 
Cr(V) + H2O2        Cr(VI) + 
•OH + OH– 
 
The formation of these radicals may be responsible for harmful effects within the cells, 
namely lipid peroxidation [81], modification of signalling pathways [82, 83] and intracellular 
constituents, like the cytoskeleton [84,85] and DNA [86]. Some studies performed in animals 
(rabbits and rodents), associate the formation of ROS induced by Cr(VI) exposure, with liver, 
testes, brain, kidney and lung injuries [87] and with activation of proteins of the matrix, 
important to cell invasion and metastasis [88]. Still, some authors defend that the formation of 
Cr-DNA adducts are the major lesions associated with the carcinogenity of Cr(VI) [79].  
The structural and functional damages induced by Cr(VI) on DNA can lead to growth 
arrest [89] and apoptosis [85,90]. The extent of the damage determines which cellular 
response is triggered. Also, Cr(VI) exposure can induce dysfunctional DNA replication, 
transcription and repair [63]. Studies with human lung cells also suggest that chromosome 
instability is associated with Cr(VI)-induced lung cancers, and the instability appears to be 
mediated through centrosome and spindle assembly checkpoint bypass [91].  
  
(1.3) 
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Fig. 1.3- General pathways involved in the genotoxicity induced by Cr. The figure illustrates the 
relationship between Cr metabolism and DNA damage. Cr6+ enters the cell via sulphate/phosphate 
transporters and is rapidly reduced by a one or two electron mechanism to Cr
3+
, which is unable to cross 
the cell membrane. An initial one-electron reduction can lead to the generation of high valent Cr species 
(Cr5+/Cr4+). Both Cr3+ and Cr5+ display an appreciable affinity for both DNA bases and the phosphate 
backbone, leading to the formation of Cr - DNA monoadducts, ICLs and ternary adducts. Cr5+ can directly 
oxidize DNA bases (guanine) and sugars (hydrogen abstraction) and produce DNA strand breaks. Cr3+ is 
the ultimate DNA reactive species and is critical for the formation of monoadducts, ICLs and DNA-
protein crosslinks. Both Cr3+ and Cr5+ may generate the hydroxyl radical in the presence of H2O2 and lead 
to oxidative DNA damage. Abbreviations: ICLs, interstrand crooslinks; H2O2, hydrogen peroxide [54]. 
 
To better understand the type of response obtained after exposure to Cr(VI), an 
excellent tool is the study of the signalling pathways affected by this metal. Studies of gene 
expression profiles have yielded many important data. Nevertheless, this data should be 
carefully analysed because exposure regimens and the type of cell line used exert different 
effects on the pattern of gene expression. The importance of adequate concentrations and 
study models used will be discussed in more detailed in section 1.3.7.  
 
1.3.6) Cr(VI)-Induced Changes of Energy Metabolism 
As mentioned before, most cancer cells exhibit a particular metabolism, and this 
situation should also be a relevant point to dissect when considering Cr(VI)-induced 
carcinogenity. Noteworthy, few studies have analysed the modifications on bioenergetic 
parameters after Cr(VI) exposure. The firsts metabolic studies performed have shown that 
Cr(VI) induces changes in oxygen consumption rate (OCR) and in the adenylate pool [92-95]. 
These studies were performed either in cultured cells [92,95,96] or in isolated mitochondria 
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[93,94]. A diminution of ATP levels concomitant with an increase of adenosine diphosphate 
(ADP) and AMP pools and alterations on the activity of complex I were observed [92-94].    
Moreover, electron spin resonance (ESR) studies showed that Cr(VI) inhibits electron 
flow through complexes I and II, an effect mediated by oxidation of the Fe-S centers present in 
these complexes [97]. Studies from the same group demonstrated that Cr(VI) interferes with 
the thioredoxin (Trx) system. This system maintains the intracellular thiol redox balance, 
promoting cell survival. Treatments with Cr(VI) promote oxidation of both cytosolic and 
mitochondrial thioredoxins isoforms, Trx1 and Trx2, respectively, interfering with the redox 
balance of the cell [98,99]. 
Studies with PC-12 cells showed that exposure to Cr(VI) at sub-cytotoxic concentration 
resulted in higher glucose uptake and lower adenylate energy charge, supporting a metabolic 
shift from OXPHOS to aerobic glycolysis [96]. 
 
1.3.7) The Influence of the Experimental Conditions in the Study of 
Cr(VI)-Induced Carcinogenity  
Cr(VI) is a well-recognized human lung carcinogen [52]. Extensive information about 
Cr(VI)  effects already exists, but the exact  mechanisms underlying Cr(VI)-induced toxicity and 
carcinogenicity remain unclear [54,63]. This situation results from the difficulty to access lung 
tumor tissue from exposed workers, making almost impossible the monitoring of molecular 
changes during the progression of the disease. As a result, further studies with adequate 
model systems and exposure regimens to the carcinogenic agent are urgently needed [63].  
Concerning the model system, the most promising choices are in vivo models, such as 
mice and rats. In this case, the restricted access to the bronchial bifurcations premains a 
problem, leaving as the only alternative the animal sacrifice for collection of the modified cells. 
This raises several problems both ethical and economical. To overcome these problems, 
cellular systems that mimic the biological process should be used. Taking into account that 
Cr(VI) exerts its effects mainly in the lung [60,61], primary epithelial lung cells are the most 
promising system. However, to evaluate the chronic effect of Cr(VI), cells must be subjected to 
chronic administrations, which requires a cell system with a relatively prolonged lifespan. Thus, 
the primary epithelial cultures should be optimized, by a transformation process, in order to 
prolong their lifespan [63]. For instance, the bronchial epithelial airway system 2B (BEAS-2B) 
cell line is an immortalized cell line derived from normal human bronchial epithelial (NHBE) 
cells through infection with an adenovirus 12-simian virus 40 (SV40) hybrid virus [100]. The 
transformation process is possible because these cells produce a SV40 T antigen that binds to 
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the tumor suppressor proteins p53 and RB, prolonging the cells’ life span [101, 102]. 
Nevertheless, this cell line maintains some characteristics of NHBE cells [103]. Few studies 
have used this cell system or a similar NHBE cell line [85,97,104,105], but instead, many were 
conducted in cells derived from other tissues or in established malignant cells [106-108]. 
Established malignant cells, such as HeLa cells, have particular phenotypes, namely metabolic 
modifications that are strongly based on glycolysis [4], and this could lead to 
misinterpretations of the results.  
Another important aspect to take into account is the type of media used in culture 
procedures, especially with metabolic experiments. BEAS-2B cells respond to serum by ceasing 
cell division and undergoing terminal squamous differentiation [103] and many studies are 
performed with media supplemented with serum. Commercial medium MEM contains several 
components that can reduce Cr(VI) immediately after its solubilisation, thus reducing the levels 
of the metal that is actually in contact with the cells [109]. Borthiry and collaborators (2008) 
[110] studied the presence of Cr(V), a product of Cr(VI) reduction in two cultures media 
(DMEM and LHC-9). After dissolution of Na2CrO4 in the culture media, and in the absence of 
cells, Cr(V) was detected by ESR spectroscopy just in the DMEM medium.  
The absence of serum from the culture media leads us to a delicate situation, since it is 
the main source of Asc in most culture media and Asc levels are rapidly diminished [111]. 
Considering that human cells seem to use Asc as the main reducer of Cr(VI) [72], its absence 
could lead to distorted results.  
Another important aspect is the selected exposure regimen, since different 
concentrations of Cr(VI) may induce different cellular responses. The amount of Cr(VI) 
administered to the cell models should be sub-cytotoxic or mildly cytotoxic, in order to mimic 
occupational exposures to this agent. The workers that are in close contact with Cr(VI)-
containing compounds are mostly exposed to low concentrations of this agent. Thus, in vitro 
studies should mimic this situation by using sub-cytotoxic concentrations and paying attention 
to the accumulation of Cr(VI) in the lung bifurcations of workers [63]. Actually, high levels of 
Cr(VI) are unlikely to induce carcinogenesis, since they may obstruct DNA replication through 
inhibition of polymerase activity [112,113]. On the other hand, lower levels of Cr(VI) can 
actually stimulate the activity of DNA polymerase. In one study where lower doses were used 
(up to 5 µM), an increase in the activity of this enzyme was detected, which may contribute to 
Cr(VI)-induced mutagenesis [112]. For instance, Alpoim and collaborators (2009) confirmed 
malignization by continuous exposure of BEAS-2B cells to a slightly cytotoxic concentration of 
Cr(VI) (1 µM), followed by low density cultivation [114]. 
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1.4) Objectives of the Present Research Work 
 
For many years Cr(VI) has been recognized by IARC as carcinogenic agent, and chronic 
exposure to Cr(VI)-containing compounds is linked to an increased risk for lung cancer 
development [52]. However, the exact mechanisms of Cr(VI)-induced carcinogenesis have not 
been fully established. In particular, the modifications of cellular metabolism, an established 
hallmark of cancer cells, during tumor progression and triggered by Cr(VI) are not dissected 
[63]. Moreover, the risk for developing lung cancer is associated with chronic exposure, but in 
vitro studies shown that Cr(VI) induce cellular modifications even after just a single insult [85, 
105].    
The main goal of this research project was to establish the effects of Cr(VI) acute 
exposures in some parameters of the energy metabolism of human bronchial epithelial cells. 
For that purpose, BEAS-2B cells, a non-malignant transformed NHBE cell line, was exposed to a 
single sub-cytotoxic concentration of Cr(VI) and the modifications of some metabolic 
parameters were evaluated. These parameters were the OCR, the glycolytic flux, the amount 
of ATP produced and levels of proteomic markers of glycolysis and mitochondria function. We 
aimed to determine the bioenergetic signature of BEAS-2B cells immediately after a single 
exposure to Cr(VI). The Cr(VI) cytotoxicity was evaluated by several methodologies, including 
the determination of the levels of ROS, protein carbonylation and clonogenic potential.  
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For specific information about the aqueous solutions used and the suppliers of 
chemicals and material please see the supplemental material. 
 
 
2.1) Materials  
 
2.1.1) BEAS-2B Cell Line 
BEAS-2B cells (Cat. No.: 95102433) were obtained from the European Collection of Cell 
Cultures (ECACC). BEAS-2B cells were derived from normal bronchial epithelium obtained in an 
autopsy of a non-cancerous individual. In order to immortalize the primary culture, cells were 
infected with a replication-defective SV40/adenovirus 12 hybrid and cloned [115]. BEAS-2B 
cells, growing as monolayers (Fig 2.1) retain the ability to undergo squamous differentiation in 
response to serum. This ability can be used for screening chemical and biological agents 
inducing or affecting differentiation and/or carcinogenesis. The cells must be subcultured 
before reaching a high confluency, because highly confluent cultures rapidly undergo 
squamous terminal differentiation [115]. The supplier recommends BEGM culture medium, 
also known as LHC-9 with modification [115]. LHC-9 is composed of basal LHC medium, as 
described in [116,117], supplemented with several growth factors, such as epidermal growth 
factor, ethanolamine, phosphoethanolamine, bovine pituitary extract [118]. LHC-9 is a serum-
free medium [116-118]. 
Fig. 2.1- BEAS-2B cell line used in the experimental work. Cells were in passage #13 and with four days 
of growing after the sub-culture procedure. Micrography acquired with a digital camera incorporated 
into an inverted microscope (Olympus), 100x.  
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2.2) Methods  
 
2.2.1) BEAS-2B Culture Procedures 
The BEAS-2B cell line was grown at 37 oC in a humidified atmosphere of 5% (v/v) CO2. 
the culture recipients used were pre-coated with a coating solution [2% gelatine; phosphate-
buffered saline (PBS); 2% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich)] for at least 2 h 
and up to 72 h. Cultures were maintained in LHC-9 growth medium (Gibco) with a depth of 200 
µL/cm2. The initial seeding density was 4,000 cells/cm2. For each different experiment, the cell 
density was adapted. On routine subculture procedures, cells were harvested using a trypsin 
solution (Sigma-Aldrich) and collected in PBS. The resulting suspension was centrifuged at 
1500 rpm for 5 min and the pellet was resuspended in a convenient volume of LHC-9 and 
dispersed into single cell suspensions. The number of cells was estimated using a 0.4% (v/v) 
trypan blue solution (Sigma-Aldrich) and a haemocytometer. To prepare cultures for 
experiments at least two independent counts were performed. Counts differing by more than 
10% were repeated. In order to ensure that cells were in the exponential phase of growth the 
subculture procedures were done every 3-4 days.  
 
2.2.2) Cr(VI) Treatments 
After the seeding procedure, cells were allowed to attach to the substrate for 24 h 
before the addition of Cr(VI). In order to obtain final concentrations of Cr(VI) ranging between 
0.1 and 2.0 µM, 10 and 100 µM Cr(VI)-containing solutions [as K2Cr2O7 (Sigma-Aldrich)] were 
used. The control cultures, established and processed in parallel, received an equivalent 
amount of the vehicle (water). 
 
2.2.3) Determination of Clonogenic Potential 
The capability of a single cell to grow into a colony after a single Cr(VI) insult was verified 
according to Franken et al (2006) [119]. Briefly, 300 cells (between passages #14 and #18) 
were seeded into 6-well plates and treated with Cr(VI) (0.1 to 2.0 µM). The medium was 
removed and replaced with fresh and warmed Cr(VI)-free medium 24, 48 and 72 h after Cr(VI) 
addition. The cultures grown for nine or ten days after the seeding procedure and the colonies 
were fixed and stained with a colony fixation-staining solution [6.0% (v/v) glutaraldehyde; 0.5% 
(w/v) crystal violet (Sigma-Aldrich)] for 75 min. Next, the colonies were washed to remove the 
excess of dye by slowly immersing the 6-well plates into a sink filled with distilled water.  
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For each condition at least duplicate cultures were seeded and the number of colonies 
was averaged in order to determine the plating efficiency. Plating efficiency is the ratio, in 
percentage, between the number of colonies and the number of cells seeded. The number of 
colonies was counted by direct observation and all colonies stained purple were scored.  
 
2.2.4) Determination of Protein Contents in Cellular Extracts 
Cells were harvested by trypsinization as described in section 2.2.1. For protein 
extraction, cells were resuspended in a lysis buffer [1.0 M tris base, pH 8; 0.5 M 
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich); 10% Triton X-100 (Merck); protease 
inhibitor (Roche)] and centrifuged at 11,000 g for 15 min at 4 oC. The supernatant containing 
the proteins was transferred to new centrifuge tubes. Bradford reagent (Bio-Rad) was used to 
determine the concentration of protein according to the manufacturer's instructions [120].  
 
2.2.5) Determination of Oxygen Consumption Rates 
 OCRs were determined using the Seahorse XF24 Analyzer (Seahorse Bioscience). The 
Seahorse XF24 Analyzer allows the determination of OCR by a non-invasive, label-free, rapid 
procedure. OCR is an indicator of mitochondrial activity, since the flow of electrons during 
OXPHOS through the respiratory chain ends up with the consumption of the terminal electron 
acceptor, molecular oxygen, which is reduced to water. The Seahorse XF24 Analyzer also 
allows the sequential delivery of four different compounds [121]. Measurements of OCR 
following addition of specific compounds allow the characterization of the bioenergetic profile 
of cells and a more comprehensive assessment of the contribution of mitochondrial activity for 
cellular energetics. Measurements are performed using optical fluorescent biosensors placed 
into XF24 analyzer microplates that detect changes in the amount of dissolved oxygen in the 
medium that is in close contact with the cells cultured in the microplates. The biosensors are 
coupled to a fibre-optic waveguide that delivers light at an excitation wavelength equal to 532 
nm to detect oxygen and transmits a fluorescent signal at 650 nm to the photodetectors [122].   
 
To assess OCRs, 20,000 cells (passage #15) were seeded into different wells of a specific 
24-well tissue culture microplate. Four wells which contained only culture medium (A1, B4, C3 
and D6) were used for temperature control. Cells were seeded in a two-step way, which 
consist of seeding the cells in 100 µL of media and adding an additional 250 µL after 2-5 h. 
Cells were exposed to 1 µM Cr(VI) for 48 h. On the day of the experiment, the culture medium 
was replaced by 700 µL of fresh Cr(VI)-free medium.  
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The four pneumatic drug ports of the sensor cartridge were sequentially loaded with 50 
µL of LHC-9 containing 6 µM oligomycin (OL, Sigma-Aldrich), 750 µM 2,4-dinitrophenol (DNP, 
Sigma-Aldrich), 1 µM rotenone (Sigma-Aldrich) and 1 µM antimycin (Sigma-Aldrich). With this 
sequence, the bioenergetic profile of BEAS-2B untreated and exposed to 1 µM Cr(VI) was 
determined.  
The OCR was expressed as pmol O2/min/μg protein.   
 
2.2.6) Determination of Lactate Levels in Culture Media 
The lactate produced by BEAS-2B cells treated and untreated with Cr(VI) was measured 
enzymatically. 
As a preliminary experiment, the initial rate of lactate production was estimated by 
exposing 500,000 cells (passage #11) seeded into 100 mm dishes to 1 µM Cr(VI) for 48 h. A 100 
µL aliquot of medium was collected at different times (0, 30, 60, 90, 120, 180, 240, 300 and 
360 min). For each collected sample, an equivalent volume of LHC-9 was added to the test 
plates.  
For the experiment, 100,000 cells (passage #11) were seeded in quadruplicate into 6-
well plates. After an exposure to 1 µM Cr(VI) for 48 h, the growth medium was replaced by 
fresh one with or without 6 µM OL or 750 µM DNP. After 240 min (4 h), aliquots of 200 µL 
were collected and cellular extracts were prepared in order to determine their protein 
content. 
Cellular sediments present in the collected medium (on both procedures) were 
precipitated with 6% perchloric acid (Merck). After 30 min on ice, the samples were 
centrifuged for 5 min at 11,000 g and 4 oC. The supernatant fractions, which contained the 
lactate, were neutralized with 20% KOH (Merck) and centrifuged at 11,000 g and 4 oC for 5 
minutes to precipitate the KClO4 salt. 
The quantification of lactate present in the samples is based in the conversion of L-lactate 
to pyruvate by the LDH (Roche) in the presence of NAD+ (Sigma-Aldrich). The NADH generated 
is spectrophotometrically detected at 340 nm (equation 2.1). 
 
L-Lactate + NAD+               Pyruvate + NADH 
  
 
 
 
(2.1) 
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2.2.7) Determination of ATP Levels in Cellular Extracts 
The levels of ATP produced by BEAS-2B cells were determined using a commercial kit 
(Roche) that exploits the capacity of luciferase to catalyze a light emitting-reaction. The 
commercial reagent contains luciferase and D-luciferin. The enzyme catalyzes the following 
reaction [123]: 
ATP + D-Luciferin + O2               Oxyluciferin + PPi + AMP + CO2 + Light 
The maximum emission peak of the resulting green light is set at 562 nm and can be 
detected with a luminometer. The light produced is directly proportional to the quantity of 
ATP present in the sample when the amount of luciferase and D-luciferin are not limitant 
[123].    
To prepare the experiments, 100,000 or 150,000 cells (between passages #14 and #19) 
were seeded in triplicate into 6-well plates. Cells were exposed to 1 µM Cr(VI) for 48 h. 
Afterwards, the growth medium was replaced by fresh one with or without 6 µM OL, 750 µM 
DNP or 100 µM 2-deoxiglucose (2-DG, Sigma-Aldrich). To disrupt the cells and release the ATP 
to the aqueous fraction, 400 µL of the ATP lysis buffer [100 mM tris base, pH 7.75; 4 mM EDTA] 
at 95 oC were added to the cells. The cellular suspension was placed at 95 oC for 2 min and 
centrifuged at 11,000 g for 15 min.  
ATP solutions with concentrations ranging from 1.6 to 1.6x106 nM were used as 
standards. The luminescence was measured in a microplate reader (BMG Labtech) that 
detected the emitted luminescence. 
The amount of ATP produced was expressed as mmol ATP/cell. 
 
2.2.8) Sodium Dodecyl Sulfate (SDS) - Polyacrylamide Gel Electrophoresis 
(PAGE) and Western Blot 
 
2.2.8.1) SDS-PAGE 
Proteins obtained from cellular extracts prepared after an exposure to Cr(VI) for 48 h 
were fractionated into SDS-PAGE following Laemmli’s method [124]. The protein samples were 
loaded into 9% polyacrylamide gels and separated using the electrophoresis buffer [150.0 mM 
tris base; 3.4 mM SDS; 192.0 mM glycine (Merck)]. Protein calibration was done using a 
protein mixture of known molecular weight (Amersham). 
 
 
(2.2) 
Materials and Methods 
 
 
25 
 
2.2.8.2) Western Blot  
The fractionated proteins were transferred to polyvinylidene fluoride (PVDF) 
membranes. The electrotransference was performed for 1 h at 100 V and 4 oC, using an 
electrotransference buffer [48 mM tris base; 20% (v/v) methanol (Sigma-Aldrich); 39 mM 
glycine (Merck)]. PVDF membranes were blocked during 1 h with a membrane blocking 
solution [5.0% (w/v) nonfat dry milk (Nestlé); 150.0 mM NaCl; 50.0 mM tris base (Sigma-
Aldrich); 0.1% (v/v) tween 20 (Merck)]. The primary and secondary antibodies used are 
detailed on Table 2.1. 
 
Table 2.1- Primary and secondary antibodies used on western blot procedures. 
Antibody Type Supplier Dilution factor Preparation 
Primary 
(1h 
incubation) 
Hsp60 (mouse) Monoclonal 
Enzo Life 
Sciences 
1:20,000 Diluted in 3% 
(v/v) BSA in a 
2 mM sodium 
azide solution 
(Sigma-
Aldrich) 
GAPDH (mouse) Monoclonal Abcam 1:20,000 
βF1 (rabbit) Polyclonal 
Obtained as 
described in 
[47] 
1:20,000 
Secondary 
(45 min 
incubation) 
Goat anti-rabbit Polyclonal 
Nordic 
Immunology 
1:5,000 Diluted in the 
membrane 
block solution 
Rabbit anti-
mouse 
Monoclonal 
Nordic 
Immunology 
1:5,000 
 
Immunoblots were developed upon incubation with the enhanced chemiluminescence 
(ECL) reagent (Gibco) based on the oxidation of luminol by the peroxidase-secondary antibody 
conjugated enzyme. Luminol is converted to a light-emitting form at 428 nm. 
The quantification of the intensity of the bands was presented as the mean of relative 
expression normalized to an intern control of gel (HCT116 cells) and to the mean value of 
respective control.   
 
2.2.9) Determination of Oxidative Stress  
The radical species produced by BEAS-2B cells were detected by flow cytometry. 
100,000 cells (passage #16) were seeded in quadruplicate into 6-well plates. Cells were 
exposed to 1 µM Cr(VI) for 48 h, treated with 6 µM OL and harvested as described on section 
2.1.1.   
To detect the amount of radical species produced by cultures of BEAS-2B, the 
commercial dye 2′-7′-dichlorodihydrofluorescein diacetate (DCFH-DA, Molecular Probes) was 
used. DCFH-DA can cross cellular membranes and, once inside cells is cleaved by esterases. A 
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relatively polar and impermeable product, 2′,7′-dichlorodihydrofluorescein (DCFH2), is formed. 
Through an oxidative reaction, DCFH2 is converted to the fluorescent product, 2′,7′-
dichlorofluorescein (DCF). Accumulation of DCF monitors the redox state of cells and the 
fluorescence can be detected at 530 nm when the sample is excited at 485 nm. The 
fluorescence detected is assumed to be proportional to the concentration of H2O2 in cells 
[125].  
After an exposure to OL for 1 h, cellular pellets were ressuspended in 300 µL of 5 µM 
DCFH-DA solution and were placed at 37 oC for 30 min (protected from light). The cellular 
suspensions were centrifuged at 1500 rpm for 5 min and the resulting pellets were dispersed 
into 200 µL of fluorescence-activated cell sorting (FACS) solution [1.0% foetal bovine serum 
(FBS, Gibco); 0.1% sodium azide in PBS]. Propidium iodide (PI, Sigma-Aldrich), 1 µL, was added 
to each sample to detect dead cells.  
The fluorescence emitted by DCF and PI was detected through the FL1 and FL3 channels 
(BD FACSalibur), respectively, and at least 10,000 events were recorded.  
 
2.2.10) Determination of Protein Carbonylation Levels 
To detect protein carbonyls on BEAS-2B cells, the commercial kit OxyBlot (Millipore) was 
used. The kit contains 2,4-dinitrophenylhydrazine (DNPH) that derivatizes the carbonyl groups 
to 2,4-dinitrophenylhydrazone (DNPhydrazone). The derivatized proteins can be separated by 
gel electrophoresis and visualized through immunoblotting. As primary antibody, the kit 
contains a rabbit anti-DNP antibody. The secondary antibody is a horseradish peroxidase-
antibody (goat anti-rabbit antibody) and the detection is done with the ECL reagent. The kit 
also provides a neutralization solution and a mixture of standard proteins with attached 
DNPhydrazone residues [126]. 
 
To determine the levels of protein carbonylation, 250,000 cells (passage #16) were 
seeded into 60 mm dishes and treated with Cr(VI) for 48 h as described in section 2.2.2. Cells 
were harvested and lysed in the lysis buffer containing 5 mM dithiothreitol (reducing agent, 
Sigma-Aldrich) to avoid undesired oxidation of proteins during lysis.  
The derivatization mixture contained the protein sample (volume equivalent to 15 µg of 
protein), 10% SDS solution (to denature the proteins) and the DNPH-containing solution. The 
reaction was performed for 15 min at room temperature. Afterwards, the neutralization 
solution was added to the prepared mixtures. In parallel, two samples containing the 
molecular weight marker and the mixture of standard proteins were prepared. The mixtures 
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were loaded into a 9% running polyacrylamide gel and the electrophoresis was performed as 
described on section 2.2.7. The incubation with the primary antibody was performed overnight 
and its dilution was 1:150. The dilution used with the secondary antibody was 1:300.  
As a loading control, the PVDF membrane was incubated with a monoclonal mouse 
primary antibody for tubulin (1:5,000; Sigma-Aldrich) for 1 h. The detection of this protein was 
performed as described before (See Table 2.1). 
 
2.2.11) Statistical Analysis 
The results obtained (except for the clonogenic assay) were statistically analysed with 
the unpaired Student’s t test, using the Excel software. The results are represented as the 
mean ± standard error of the mean (SEM). Differences with a P < 0.05 and P < 0.001 were 
considered statistically significant. 
Multiple variances (time and concentration) present in the clonogenic assays were 
statistically analysed with the two-way ANOVA model and the Bonferroni’s post hoc test. The 
results are represented as the mean ± SEM. *P < 0.05 was considered statistically significant. 
The analysis was performed with the Graphpad Prism Software.  
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3.1) Short-Term Exposure to Sub-Cytotoxic Concentrations of Cr(VI) 
has no Effect in the Clonogenic Potential of BEAS-2B Cells 
 
In a previous study performed by our group [85], the cytotoxic effects of Cr(VI) at low 
concentrations were assessed using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) assay and testing the effects of different concentrations of Cr(VI) (0.1 to 4.0 
µM) for 24, 48 and 72 h exposures. The results obtained showed a dose-dependent cytotoxic 
effect for Cr(VI), with a clear threshold of toxicity between 2 and 4 M. For the low cytotoxicity 
concentrations (≤ 2 µM), increasing the incubation time from 24 to 48 and then to 72 h did not 
produce a further decrease in the viability of the treated cultures, but rather the reverse. The 
fact that the relative number of viable cells actually increased when the incubation time was 
extended indicated that those cells that survived increased their proliferating rates, suggesting 
a mitogenic effect for Cr(VI) at low levels. To further investigate the effects of Cr(VI), the 
colony-forming capacity of BEAS-2B cells exposed to low Cr(VI) concentrations exposure was 
analysed (Fig 3.1). 
Fig. 3.1- Short-term exposure to Cr(VI) at sub-cytotoxic concentrations has no statistically significant 
effect in the colony forming potential of BEAS-2B cells. 300 cells were seeded and exposed to 0.1, 0.5, 
1.0 and 2.0 µM Cr(VI) concentrations for 24, 48 and 72 h. The clonogenic potential of BEAS-2B cells was 
determined by counting the number of colonies formed after fixation and staining. Multiple 
comparisons by analysis of variance were done with two-way ANOVA model and the post hoc 
Bonferroni’s test confirmed that there were no significant differences (P > 0.05). The results shown are 
the mean ± SEM of 3 independent experiments. 
 
The clonogenic potential of BEAS-2B cells was not statistically significant affected by an 
acute exposure to Cr(VI) at low concentrations. In fact, the capacity of Cr(VI) treated-cells to 
form colonies was much similar to that of control cells. Though, exposure to 0.5 µM Cr(VI) 
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seemed to induce a slight increase in the clonogenic potential of cells over time (24 for 48 h 
and then to 72 h). On the other hand, the highest Cr(VI) concentration (2 µM) for the longest 
exposure, appeared to be a slightly cytotoxic and the platting efficiency diminished when 
compared to control (Fig. 3.1). In this case, the clonogenic potential of BEAS-2B cells seems to 
be slightly affected (P = 0.0523) by time exposure (Fig. 3.1). 
A comparison of the results obtained in the MTT [85] and in the clonogenic assay, 
suggests that lower Cr(VI) levels specifically killed those cells in culture that exhibited the 
lowest clonogenic capacities and/or increased the clonogenic survival of those cells that 
resisted the acute insult.  
 
Overall, these results led us to chose the 1 µM concentration at 48 h to further 
investigate the effects of Cr(VI) on the energy metabolism of BEAS-2B cells.  
 
3.2) Short-Term Exposure to 1 µM Cr(VI) Alters the Oxygen 
Consumption Rate and the Maximum Respiratory Rate of 
BEAS-2B Cells  
 
In order to better understand the effects that short exposures to 1 µM Cr(VI) had on the 
energy metabolism of BEAS-2B cells, the rates of oxygen consumption were determined. OCRs 
were assessed using the XF24 Extracellular Flux Analyzer, an instrument that allows the 
determination of OCR in adherent live cells [127]. 
To determine the bioenergetic profile of BEAS-2B cells, the basal OCR was measured, 
followed by the sequential addition of OL, DNP, rotenone and antimycin (Fig. 3.2). This specific 
sequence allows the determination of OL-sensitive respiration, the maximal respiration and 
oxygen consumption due to the activity of complexes I and complex III, respectively [128].  
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Fig. 3.2- Short-term exposure to 1 µM Cr(VI) induces a decrease in the OCR of BEAS-2B cells. 20,000 
cells were seeded and treated with Cr(VI) for 48 h. (A) Bioenergetic profile obtained after real-time 
analysis of OCR in XF24 Extracellular Flux Analyzer of untreated and 1 µM Cr(VI)-treated BEAS-2B cells. 
The arrows represent the sequential addition of 6 µM OL, 750 µM DNP, 1 µM ROT and 1 µM ANT. (B) 
Histograms representing the OCR in basal conditions and after DNP addition. Data showed are the mean 
± SEM for 8 determinations. *P < 0.05 when compared with control values by Student’s t test; 
#
P < 0.05 
when compared with the respective basal value by Student’s t test. Abbreviations: OCR, oxygen 
consumption rate; OL, oligomycin; DNP, 2,4-dinitrophenol; ROT, rotenone; ANT, antimycin. 
 
Cr(VI)-treated cells and control cells have a similar bioenergetic profile (Fig. 3.2A), but 
the former revealed a significantly lower basal and uncoupler-stimulated OCRs. The OCR 
diminished after OL injection, but no significant differences were obtained between treated 
and untreated cultures. Very interestingly, cells exposed to Cr(VI) did not show statistically 
significant differences between the basal and the maximal respiratory rates (after DNP 
injection), whereas control cells did. The mean value of OCR in control cells was approximately 
20 pmol O2/min/µg protein, whereas Cr(VI)-treated cells displayed an OCR of about 15 pmol 
O2/min/µg protein (Fig 3.2B – DNP bars). Overall, the results indicate that Cr(VI) is interfering 
with the maximum respiratory capability of cells. Rotenone induce a large decrease in the OCR, 
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both in control and Cr(VI)-exposed cultures, setting the values of OCR close to zero (2.21±0.23 
and 1.89±0.13 pmol O2/min/µg protein for control and Cr(VI)-exposed cells, respectively).  
 
3.3) Short-Term Exposure to 1 µM Cr(VI) Alters the Basal and the 
Maximal Glycolytic Flux of BEAS-2B Cells  
 
To further investigate the effect of short-term exposures to 1 µM Cr(VI) in the glycolytic 
flux of the cells, the levels lactate in the culture media were measured after 48 h of Cr 
exposure. In order to assess the initial rate of lactate production, a preliminary experiment was 
done, in which the release of lactate into the medium was followed for 360 minutes (Fig. 3.3A). 
Afterwards, the levels of lactate production were determined at a selected time point (240 
min) after treatment with OL and DNP (Fig. 3.3B).  
 Fig. 3.3- Short-term exposure to 1 µM Cr(VI) stimulates the initial rate of lactate production and 
increase basal and maximum glycolytic fluxes. (A) 500,000 cells were exposed to 1 µM for 48 h. Lactate 
levels were assessed enzymatically as described under Material and Methods. (B) 100,000 cells were 
exposed to 1 µM for 48 h and the concentration of lactate in the medium was determined enzymatically 
4 h after treatment of cells with 6 µM OL (4 h) and 750 µM DNP (1 h). (B) The results shown are the 
mean ± SEM of 4 determinations. *P < 0.05 when compared with control values by Student’s t test; #P < 
0.05 and ##P < 0.001 when compared with the respective basal value by Student’s t test. Abbreviations: 
OL, oligomycin; DNP, 2,4-dinitrophenol.   
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Both control and Cr(VI)-exposed cells showed roughly a linear production of lactate 
during the first 6 h (Fig. 3.3A). Short-term exposure of BEAS-2B to this sub-cytotoxic 
concentration of Cr(VI) significantly increased the basal rate of lactate production when 
compared with controls (Fig. 3.3B). Inhibition of the H+-ATP synthase with OL significantly 
increased the rates of aerobic glycolysis in both control and Cr(VI)-treated cells (Fig. 3.3B). 
Cr(VI) treatment increased significantly the maximum lactate production rates as determined 
in the presence of the mitochondrial uncoupler DNP. Moreover, a higher maximum glycolytic 
flux was observed in Cr(VI)-treated cells when compared with controls (Fig. 3.3B). Overall, 
these results demonstrate that short-term treatment of Cr increases the glycolytic flux of 
human bronchial epithelial cells.   
 
3.4) Short-Term Exposure to 1 µM Cr(VI) had no Effects in the Levels 
of ATP of BEAS-2B Cells  
 
The levels of ATP produced by BEAS-2B cells were determined after a 48 h exposure to 
Cr(VI) and in control cells (Fig. 3.4). 
Fig. 3.4- Short-term exposure to 1 µM Cr(VI) does not significantly affect the production of ATP. BEAS-
2B cells were exposed to 1 µM Cr(VI) for 48 h. Cells were then treated with the following agents: 6 µM 
OL, 750 µM DNP and 100 µM 2-DG, or left untreated (basal) and the intracellular concentration of ATP 
was determined. The histograms represent the means ± SEM of 3 independent experiments. *P < 0.05, 
and **P < 0.001, when compared with the respective basal value by Student’s t test, respectively. 
Abbreviations: ATP, adenosine triphosphate; OL, oligomycin; DNP, 2,4-dinitrophenol; 2-DG, 2-
deoxyglucose.  
 
The exposure of BEAS-2B cells to Cr(VI) for a 48 h period did not affect the intracellular 
basal ATP levels (Fig. 3.4). However, a significant and similar drop in cellular ATP levels was 
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observed when aerobic glycolysis was inhibited with 2-DG or when the H+-ATP synthase was 
inhibited with OL (Fig. 3.4). Overall, these data suggest that glycolysis and OXPHOS contributed 
equally to energy production in BEAS-2B cells. Interestingly, we observed that DNP promoted a 
slight drop in ATP levels in both control and Cr(VI)-treated cells, when compared with OL or 2-
DG-treated cells. These findings indicate that the large stimulation of glycolysis triggered by 
DNP treatment (see Fig. 3.3B) compensates the energetic imbalance imposed by uncoupling 
energy transduction in the mitochondria.  
 
3.5) Short-Tem Exposure to 1 µM Cr(VI) Alters the Expression of 
Glycolytic and Mitochondrial Proteins and the Bioenergetic 
Signature of BEAS-2B Cells  
 
The levels of the cytosolic GAPDH protein and the mitochondrial Hsp60 and βF1 proteins 
were determined in control and in treated cells with Cr(VI) to for  48 h (Fig. 3.5).  
Fig. 3.5- Short-term exposure to 1 µM Cr(VI) alters the expression of glycolytic and mitochondrial 
markers. (A) Representative western blot of the expression of Hsp60, βF1 and GAPDH in two different 
preparations of untreated and 1 µM Cr(VI)-treated cells with for 48 h. (B) Histograms representing the 
relative expression (mean ± SEM) of βF1 (n=14), GAPDH (n=13) and Hsp60 (n=11) and the βF1:GAPDH 
(n=14) and the βF1:Hsp60 (n=11) ratios. The expression was normalized to an internal control (extracts 
of HCT116 cells) assayed in all the gels and expressed relative to the mean value of untreated cells. *P < 
0.05 when compared with control conditions by Student’s t test. Abbreviations: Hsp60, heat shock 
protein 60; βF1, β-F1-ATPase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MW, molecular 
weight. 
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Consistent with glycolytic flux and OCR data, the expression of GAPDH was significantly 
increased in Cr(VI)-treated cells (Fig. 3.5). Moreover, treatment of cells with Cr(VI) resulted in 
the down-regulation of the βF1 catalytic subunit of the H+-ATP synthase. Changes in the 
expression of βF1 occurred in the absence of statistically relevant changes in the expression of 
the structural mitochondrial protein Hsp60. Therefore, the ratio βF1/GAPDH (bioenergetic 
signature) was significantly diminished in Cr(VI)-treated cells. No significant changes were 
observed in the βF1/Hsp60 ratio (Fig. 3.5B).  
 
3.6) Short-Term Exposure to 1 µM Cr(VI) Induces the Production of 
Oxidative Stress after Oligomycin Treatment  
 
In order to further investigate the toxicity that Cr(VI) may induce in BEAS-2B cells, we 
analysed the production of oxidative stress by flow cytometry (Fig. 3.6).  
Treatment of BEAS-2B cells with 1 µM Cr(VI) did not interfere with the  basal production 
of radical species (Fig. 3.6B). However, whereas the treatment with OL did not promote 
significant changes in the production of radical species in control cells, Cr(VI)-treated cells 
showed a significant increase in the levels of oxidative stress after the addition of OL (Fig. 
3.6B). 
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Fig. 3.6– Short-term exposure to Cr(VI) induces the production of oxidative stress in OL-treated cells. 
(A) 100,000 cells were seeded and exposed to 1 µM Cr(VI) for 48 h. Cells were treated with OL for 1 h 
and the oxidative stress was detected by flow cytometry. At least, 10,000 events were recorded. (B) The 
histograms represent the means ± SEM. **P < 0.001 when compared with control values by Student’s t 
test; ##P < 0.001 when compared with the respective basal value by Student’s t test Abbreviations: OL, 
oligomycin. 
 
Free radicals that are not detoxified by the cellular defences can attack and modify 
components, such as nucleic acids, lipids and proteins [129]. Consistent with the lack of 
differences in basal ROS production between control and Cr(VI)-treated cells, we observed that 
cellular proteins carbonylation was altered by treatment with 1 µM Cr(VI) (Fig. 3.7A). The 
quantification of p50, a representative band to a 50 KDa protein (Fig. 3.7B), supported the 
absence of significant differences between Cr(VI)-treated and control cells. 
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Fig. 3.7- Short-term exposure to 1 µM Cr(VI) does not alter the levels of carbonylation of cellular 
proteins. (A) Representative western blot of the levels of protein carbonyls in two different preparations 
of untreated and treated cells with 1 µM Cr(VI) for 48 h. (B) Histogram representing the mean ± SEM of 
the relative expression (normalized with tubulin expression levels) of the carbonyls detected in the 
protein with a molecular weight of 50 KDa (n=4). *P < 0.05 when compared with control conditions by 
Student’s t test. Abbreviations: MW, molecular weight.  
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For a long time, Cr(VI) has been established as a carcinogenic agent, predisposing 
primarily to squamous lung cancer [52]. Nevertheless, the mechanisms underlying Cr(VI)-
induced carcinogenesis are not fully understood. Most studies focused mainly on the genotoxic 
characteristics of Cr(VI) and few have explored the possible modifications induced by Cr(VI) on 
the cellular energy metabolism after short-term exposure to the metal. This poses a problem, 
since the deregulation of cellular energetics in lung cancer is a hallmark fulfilled by more than 
97% of both squamous and adenocarcinomas of the lung [48,51].  
To better understand the effects of Cr(VI) on lung cells we chose a transformed NHBE 
cell line to conduct the metabolic studies. BEAS-2B is an immortalized and non-tumorigenic cell 
line derived from normal human epithelium that strongly resembles the main in vivo target of 
Cr(VI) carcinogenicity [103,115]. The concentrations of Cr(VI) used in our experiments were 
chosen in an attempt to mimic the levels of soluble Cr(VI) concentrations found in the lungs of 
chromate workers exposed. Tsuneta and colleagues (1980) found in peripheral lung tissues a 
mean Cr(VI) concentration of about 40 µg per g wet weight in chromate workers with lung 
cancer [60]. According to Caglieri et al (2008), the concentrations applied by us in BEAS-2B cells 
are comparable to the levels found in those lungs [105]. Therefore, we suggest that the results 
obtained in our in vitro studies can be useful to better understand the effects of Cr(VI) in 
exposed workers. 
To explore the cytotoxicity of Cr(VI) at low levels in BEAS-2B cells we performed a 
clonogenic assay, testing different concentrations and several exposure periods (Fig. 3.1). 
None of the concentrations significantly affect the potential of cells to form colonies. The 
platting efficiency of cells exposed to 2 µM Cr(VI) for 72 h slightly decreased, suggesting that 
this concentration may be cytotoxic. In a previous study [85] where the viability of cells was 
tested with the MTT assay, the threshold of Cr(VI) toxicity was also set between 2 and 4 µM. 
Interestingly, lower levels of Cr(VI) appeared to increased the viability of cells [85]. In the 
clonogenic assay, lower levels did not interfere with the capability of cells to form colonies, 
suggesting that Cr(VI) may increase the clonogenic survival of cells more resistant to it, or that 
it selectively may kills the cells with lower potential to form colonies. In other studies, 16 h 
Cr(VI) treatments with 2.5 and 5 µM doses resulted in a marked decrease in the clonogenic 
survival of cells [99]. Higher levels of Cr(VI) are unlikely to induce carcinogenesis, due to 
polymerase arrest, whereas lower levels may stimulate the activity of the enzyme [112,113]. 
Overall, the mutagenic and transforming actions of Cr(VI) may occur at very low levels (< 2 µM) 
of exposure.   
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The subsequent studies aimed to investigate the effects of the metal on energy 
metabolism of BEAS-2B cells were performed with a single concentration of Cr(VI), 1 µM. The 
levels of Cr(VI) decreased in the culture medium, over time, due to its fast transport through 
the anion carrier [67]. Considering this situation, the different analyses carried out were not 
performed after long time-period of incubation with Cr(VI) (72 h), because many cells may not 
even be in contact with Cr(VI), and the effects of the metal will be diluted. Moreover, shorter 
times of incubation also prevented an excessive degree of confluence of cultures and the 
entrance into the stationary phase due to contact inhibition. An exposure period of 24 h was 
considered insufficient to observe modifications in some of the analysed parameters, 
particularly, in the expression of proteins. So, we decided to treat cells with 1 µM Cr(VI) for 48 
h. 
The results clearly showed that a single insult of 1 µM Cr(VI) interferes with the activity 
of mitochondria in these human bronchial epithelial cells. The bioenergetic analysis with the 
XF24 Extracellular Flux Analyzer demonstrated that Cr(VI) diminished the consumption of O2 in 
BEAS-2B cells by interfering with both the basal and uncoupler stimulated respiratory activity 
of mitochondria (Fig. 3.2). These changes occurred concurrently with an increase in the 
glycolytic flux. The effect of Cr(VI) toxicity in the energy metabolism is better illustrated by the 
large differences observed in aerobic glycolysis of the cells subjected to stressful conditions, 
such as when the cells were incubated in the presence of the uncoupler DNP (Fig. 3.3). 
Moreover, proteomic analysis of both glycolytic and mitochondrial proteins confirmed these 
findings showing a diminished expression of βF1 concomitant with an increased GAPDH (Fig. 
3.5), which is translated into a lower overall mitochondrial potential (lower BEC Index). The 
analysis of the expression levels of GAPDH, Hsp60 and F1 proteins in different types of solid 
tumors demonstrated that malignant cells display a lower BEC Index (F1/GAPDH ratio) [12, 
48, 49].Remarkably, our findings illustrate that a short-term exposure of bronchial epithelial 
cells to a single insult of 1 µM Cr(VI) triggers modifications in the energy metabolism similar to 
the ones found in carcinomas. The over-expression of GAPDH in Cr(VI)-treated cells correlates 
positively with higher rates of an aerobic glycolytic flux. Exposed cells produce more lactate 
than controls and have an enhanced capacity to stimulate the glycolytic flux when the activity 
of mitochondria is compromised.  
In carcinomas a lower βF1/Hsp60 ratio was also found that indicates a reduction of the 
bioenergetic competence of mitochondria [12,48,49]. A single and sub-cytotoxic concentration 
of Cr(VI) appears not to affect the expression level of Hsp60 protein and the effects in the F1 
appears to be insufficient to interfere with the bioenergetic capacity of the cells. Consistent 
Discussion 
 
 
41 
 
with this observation is the finding that Cr(VI) did not interfere with the production of ATP in 
Cr(VI) treated cells, when compared with the respective basal value. In previous studies, it was 
demonstrated that Cr(VI) affects the capability of cultured hamster fibroblasts to produce ATP 
but, the doses administrated in those studies were in the millimolar range [92,130] and much 
higher than the one used in this study. We suggest that probably it is necessary higher doses or 
prolonged exposures to Cr(VI) to interfere with the capability of cells to produce their energy.  
Cr(VI) treatment displays a bioenergetic signature and a shift to glycolysis, by modifying 
the expression of key enzymes of the energy metabolism. The effects of Cr(VI) in OXPHOS are 
not translated into lower levels of ATP production, but the OCR is affected, indicating that 
somehow Cr(VI) is interfering with the activity of the electron transport chain. Myers and 
colleagues (2010) have demonstrated that Cr(VI) diminished the activity of complexes I and II 
and of that the mitochondrial aconitase. Aconitase is a TCA cycle enzyme and its inhibition will 
probably slow the production of NADH, the source of electrons to complex I, which could 
contribute to diminish the activity of the respiratory chain [97]. Moreover, specific inhibitors of 
aconitase caused a decrease in the consumption of O2 [131], reinforcing the hypothesis of the 
effect of Cr(VI) in interfering with the electron transport. In addition, in rat liver mitochondria 
Cr(VI) causes a partial inhibition of the activity of complexes I and II [94].    
Many studies have related the toxicity of Cr(VI) with the production of oxidative stress 
inside cells [76-78]. A short exposure to 1 µM Cr(VI) did not induced the basal production of 
oxidative stress nor the carbonylation of proteins. Only when Cr(VI)-exposed cells were 
stressed by treatment with OL, they did show higher levels of oxidative stress. OL is a specific 
inhibitor of the ATP synthase, by blocking its proton channel. By doing so, the protons tend to 
accumulate in the mitochondrial inter-membrane space triggering a Δψm increase [132]. Higher 
values of Δψm are associated with ROS formation [7]. Probably, the intracellular levels of anti-
oxidants in Cr(VI)-treated cells were altered when compared with control cells and the 
treatment with OL had a more pronounced effect in Cr(VI) treated cells. Some studies have 
demonstrated that Cr(VI) interfered with the Trx system, which is responsible for maintenance 
of intracellular thiol redox balance. For instance, exposure for 16 h to 5 µM Cr(VI) induced a 
complete oxidation of the mitochondrial Trx2 and peroxiredoxin 3 proteins [99]. It is likely that 
the capability of Cr(VI)-treated cells to maintain the thiol balance and detoxify free radicals is 
compromised in these extreme incubation conditions. 
Overall, we demonstrated for the first time that a short-term exposure of human 
bronchial epithelial cells to a sub-cytotoxic concentration of Cr(VI) triggers a rapid remodelling 
of the cellular energy metabolism by affecting the mitochondrial respiratory capacity and the 
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enhancement of aerobic glycolysis. These findings might be at the heart of lung cancer 
induction/progression.
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Cr(VI) is a well-recognized carcinogenic agent and prolonged exposures are 
associated with development of lung cancer [52]. In this work, we were interested in 
determining the effects of a single exposure to Cr(VI) in the energy metabolism of human 
bronchial epithelial cells using as paradigm the BEAS-2B cells. We can conclude: 
 
1) Sub-cytotoxic doses of Cr(VI) (0.5-1.0 µM) that were previously shown to have a 
mitogenic effect did not interfere with the colony forming potential of BEAS-2B 
cells.  
 
2) 1 µM Cr(VI)-treated cells had a lower basal and uncoupler-stimulated OCR when 
compared with control cells.  
 
3) 1 µM Cr(VI)-treated cells showed higher basal and stressed rates of aerobic 
glycolysis. 
 
4) Cr(VI)-treated cells showed a reduction in their bioenergetic signature when 
compared with non-treated cells in agreement with changes in the energy 
metabolism.  
 
5) 1 µM Cr(VI) treatment did not alter the basal production of oxygen radicals nor 
induced differences in the carbonylation of cellular proteins. Nevertheless, Cr(VI)-
treated cells exposed to OL increased the production of ROS when compared with 
control cells.   
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 6 
REFERENCES 
 
 
References 
 
 
46 
 
1. Berg, J.M., J.L. Tymoczko, and L. Stryer, Biochemistry (2002), 5th Edition, W. H. Freeman 
and Company, New York 
2. Nelson, D.L. and M.L. Cox, Lehninger - Principles of Biochemistry (2005), 4th Edition, W. 
H. Freeman and Company, New York 
3. Bartrons, R. and J. Caro, Hypoxia, Glucose Metabolism and the Warburg’s Effect. J 
Bioenerg Biomembr (2007), 39: 223-229 
4. Ortega, Á.D., M. Sánchez-Aragó, D. Giner-Sánchez, L. Sánchez-Cenizo, I. Willers, and J.M. 
Cuezva, Glucose Avidity of Carcinomas. Cancer Lett (2009), 276: 125-135 
5. Alberts, B., A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter, Molecular Biology of 
the Cell (2008), 5th Edition, Garland Science, New York 
6. Kirches, E., Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer 
Curr Genomics (2009), 10: 281-293 
7. H  emann, M., I. Lee, A. Pecinova, P. Pecina, K. Przyklenk, and J.W. Doan, Regulation of 
Oxidative Phosphorylation, the Mitochondrial Membrane Potential, and Their Role in 
Human Disease. J Bioenerg Biomembr (2008), 40: 445-456 
8. Santamaría, G., M. Martínez-Diez, I. Fabregat, and J. M. Cuezva, Efficient Execution of 
Cell Death in Non-Glycolytic Cells Requires the Generation of ROS Controlled by the 
Activity of Mitochondrial H+-ATP synthase. Carcinogenesis (2006), 27: 925-935 
9. Hanahan, D. and R.A. Weinberg, The Hallmarks of Cancer. Cell (2000), 100: 57-70 
10. Hanahan, D. and R.A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell (2011), 
144(5): 646-674 
11. DeBerardinis, R.J., J.J. Lum, G. Hatzivassiliou, and C.B. Thompson, The Biology of Cancer: 
Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cell Metab (2008), 7(1): 
11-20 
12. López-Ríos, F., M. Sánchez-Aragó, E. García-García, Á.D. Ortega, J.R. Berrendero, F. Pozo-
Rodríguez, Á. López-Encuentra, C. Ballestín, and J.M. Cuezva, Loss of the Mitochondrial 
Bioenergetic Capacity Underlies the Glucose Avidity of Carcinomas. Cancer Res (2007), 
67(19): 9013-9017 
13. Warburg, O., On the Origin of Cancer Cells. Science (1956), 123(3191): 309-314 
14. Warburg, O. The Prime Cause and Prevention of Cancer in Meeting of the Nobel-
Laureates (1966), Lindau, Lake Constance, Germany 
15. Garber, K., Energy Deregulation: Licensing Tumors to Grow. Science (2006), 312(5777): 
1158-9 
16. Weinhouse, S., The Warburg Hypothesis Fifty Years Later. Z Krebsforsch Klin Onkol 
Cancer Res Clin Oncol (1976), 87(2): 115-26 
17. Krebs, H., Otto Warburg: Cell Physiologist, Biochemist and Eccentric (1981), Clarendon, 
Oxford, UK 
18. Rigo, P., P. Paulus, B.J. Kaschten, R. Hustinx, T. Bury, G. Jerusalem, T. Benoit, and J. 
Foidart-Willems, Oncological Applications of Positron Emission Tomography with 
Fluorine-18 Fluorodeoxyglucose. Eur J Nucl Med (1996), 23(12): 1641-74 
19. Hsu, P.P. and D.M. Sabatini, Cancer Cell Metabolism: Warburg and Beyond. Cell (2008), 
134: 703-707 
References 
 
 
47 
 
20. Denko, N.C., Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour. Nat Rev Cancer 
(2008), 8: 705-713 
21. Semenza, G.L., HIF-1 and Tumor Progression: Pathophysiology and Therapeutics. Trends 
Mol Med (2002), 8(4 (Suppl.)) 
22. Jr, W.G.K., The von Hippel-Lindau Tumor Suppression Protein: O2 Sensing and Cancer. Nat 
Rev Cancer (2008), 8: 865-873 
23. Semenza, G.L., P.H. Roth, H.M. Fang, and G.L. Wang, Transcriptional Regulation of Genes 
Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1. J Biol Chem (1994), 269(38): 
23757-63 
24. Firth, J.D., B.L. Ebert, and P.J. Ratcliffe, Hypoxic Regulation of Lactate Dehydrogenase A. 
Interaction Between Hypoxia-Inducible Factor 1 and cAMP Response Elements. J Biol 
Chem (1995), 270(36): 21021-21027 
25. Ebert, B.L., J.D. Firth, and P.J. Ratcliffe, Hypoxia and Mitochondrial Inhibitors Regulate 
Expression of Glucose Transporter-1 Via Distinct Cis-Acting Sequences. J Biol Chem 
(1995), 270(49): 29083-9 
26. Fukuda, R., H. Zhang, J.-w. Kim, L. Shimoda, C.V. Dang, and G.L. Semenza, HIF-1 
Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic 
Cells. Cell (2007), 129(1): 111-122 
27. Dang, C.V., J.-w. Kim, P. Gao, and J. Yustein, The Interplay Between MYC and HIF in 
Cancer. Nat Rev Cancer (2008), 8(1): 51-56 
28. Pastorino, J.G., J.B. Hoek, and N. Shulga, Activation of Glycogen Synthase Kinase 3b 
Disrupts the Binding of Hexokinase II to Mitochondria by Phosphorylating Voltage-
Dependent Anion Channel and Potentiates Chemotherapy-Induced Cytotoxicity. Cancer 
Res (2005), 65(22): 10545-10554 
29. da-Silva, W.S., A. Gómez-Puyou, M.T.d. Gómez-Puyou, R. Moreno-Sanchez, F.G.D. Felice, 
L.d. Meis, M.F. Oliveira, and A. Galina, Mitochondrial Bound Hexokinase Activity as a 
Preventive Antioxidant Defense: Steady-State ADP Formation as a Regulatory 
Mechanism of Membrane Potential and Reactive Oxygen Species Generation in 
Mitochondria. J Biol Chem (2004), 279(38): 39846-39855 
30. Mathupala, S.P., Y.H. Ko, and P.L. Pedersen, Hexokinase-2 Bound to Mitochondria: 
Cancer’s Stygian Link to the “Warburg Effect” and a Pivotal Target for Effective Therapy. 
Semin Cancer Biol (2009), 19: 17-24 
31. Pastorino, J.G. and J.B. Hoek, Regulation of Hexokinase Binding to VDAC. J Bioenerg 
Biomembr (2008), 40(3): 171-182 
32. Zhang, H., P. Gao, R. Fukuda, G. Kumar, B. Krishnamachary, K.I. Zeller, Chi V. Dang, and 
G.L. Semenza, HIF-1 Inhibits Mitochondrial Biogenesis and Cellular Respiration in VHL-
Deficient Renal Cell Carcinoma by Repression of C-MYC Activity. Cancer Cell (2007), 
11(5): 407-420 
33. Kim, J.-w. and C.V. Dang, Cancer’s Molecular Sweet Tooth and the Warburg Effect. 
Cancer Res (2006), 66(18): 8927-8930 
34. Rathmell, J.C., C.J. Fox, D.R. Plas, P.S. Hammerman, R.M. Cinalli, and C.B. Thompson, Akt-
Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote 
Growth Factor-Independent Survival. Mol Cell Biol (2003), 23(20): 7315-7328 
References 
 
 
48 
 
35. Elstrom, R.L., D.E. Bauer, M. Buzzai, R. Karnauskas, M.H. Harris, D.R. Plas, H. Zhuang, 
R.M. Cinalli, A. Alavi, C.M. Rudin, and C.B. Thompson, Akt Stimulates Aerobic Glycolysis 
in Cancer Cells. Cancer Research (2004), 64(11): 3892-3899 
36. Govindarajan, B., J.E. Sligh, B.J. Vincent, M. Li, J.A. Canter, B.J. Nickoloff, R.J. Rodenburg, 
J.A. Smeitink, L. Oberley, Y. Zhang, J. Slingerland, R.S. Arnold, J.D. Lambeth, C. Cohen, L. 
Hilenski, K. Griendling, M. Martínez-Diez, J.M. Cuezva, and J.L. Arbiser, Overexpression of 
Akt Converts Radial Growth Melanoma to Vertical Growth Melanoma. J Clin Invest 
(2007), 117(3): 719-729 
37. Hatzivassiliou, G., F. Zhao, D.E. Bauer, C. Andreadis, A.N. Shaw, D. Dhanak, S.R. 
Hingorani, D.A. Tuveson, and C.B. Thompson, ATP citrate Lyase Inhibition can Suppress 
Tumor Cell Growth. Cancer Cell (2005), 8(4): 311-321 
38. Matoba, S., J.-G. Kang, W.D. Patino, A. Wragg, M. Boehm, O. Gavrilova, P.J. Hurley, F. 
Bunz, and P.M. Hwang, p53 Regulates Mitochondrial Respiration. Science (2006), 
312(5780): 1650-1653 
39. Levine, A.J., Z. Feng, T.W. Mak, H. You, and S. Jin, Coordination and Communication 
Between the p53 and IGF-1–AKT–TOR Signal Transduction Pathways. Genes Dev (2006), 
20: 267-275 
40. Kondoh, H., M.E. Lleonart, J. Gil, J. Wang, P. Degan, G. Peters, D. Martinez, A. Carnero, 
and D. Beach, Glycolytic Enzymes Can Modulate Cellular Life Span. Cancer Res (2005), 
65(1): 177-185 
41. Bonora, E., A.M. Porcelli, G. Gasparre, A. Biondi, A. Ghelli, V. Carelli, A. Baracca, G. 
Tallini, A. Martinuzzi, G. Lenaz, M. Rugolo, and G. Romeo, Defective Oxidative 
Phosphorylation in Thyroid Oncocytic Carcinoma Is Associated with Pathogenic 
Mitochondrial DNA Mutations Affecting Complexes I and III. Cancer Res (2006), 66(12): 
6087-6096 
42. Pelicano, H., D.S. Martin, R.-H. Xu, and P. Huang, Glycolysis Inhibition for Anticancer 
Treatment. Oncogene (2006), 25: 4633-4646 
43. Penta, J.S., F.M. Johnson, J.T. Wachsman, and W.C. Copeland, Mitochondrial DNA in 
Human Malignancy. Mutat Res (2001), 488(2): 119-133 
44. Gottlieb, E. and I.P.M. Tomlinson, Mitochondrial Tumor Suppressors: a Genetic and 
Biochemical Update. Nat Rev Cancer (2005), 5: 857-866 
45. Pollard, P.J., J.J. Brière, N.A. Alam, J. Barwell, E. Barclay, N.C. Wortham, T. Hun, M. 
Mitchell, S. Olpin, S.J. Moat, I.P. Hargreaves, S.J. Heales, Y.L. Chung, J.R. Griffiths, A. 
Dalgleish, J.A. McGrath, M.J. Gleeson, S.V. Hodgson, R. Poulsom, P. Rustin, and I.P.M. 
Tomlinson, Accumulation of Krebs Cycle Intermediates and Over-Expression of HIF1a in 
Tumours Which Result from Germline FH and SDH Mutations. Hum Mol Genet (2005), 
14(15): 2231-2239 
46. Cuezva, J.M., Á.D. Ortega, I. Willers, L. Sánchez-Cenizo, M. Aldea, and M. Sánchez-Aragó, 
The Tumor Suppressor Function of Mitochondria: Translation into the Clinics. Biochim 
Biophys Acta (2009), 1792(12): 1145-1158 
47. Cuezva, J.M., M. Krajewska, M.L.D. Heredia, S. Krajewski, G. Santamaría, H. Kim, J.M. 
Zapata, H. Marusawa, M. Chamorro, and J.C. Reed, The Bioenergetic Signature of 
Cancer: A Marker of Tumor Progression. Cancer Res (2002), 62: 6674-6681 
References 
 
 
49 
 
48. Isidoro, A., M. Martínez, P.L. Fernández, Á. Ortega, G. Santamaría, M. Chamorro, J.C. 
Reed, and J.M. Cuezva, Alteration of the Bioenergetic Phenotype of Mitochondria is a 
Hallmark of Breast, Gastric, Lung and Oesophageal Cancer. Biochem J (2004), 378: 17-20 
49. Cuezva, J.M., M. Sánchez-Aragó, S. Sala, A. Blanco-Rivero, and Á.D. Ortega, A Message 
Emerging from Development: the Repression of Mitochondrial β-F1-ATPase Expression in 
Cancer. J Bioenerg Biomembr (2007), 39: 259–265 
50. Isidoro, A., E. Casado, A. Redondo, P. Acebo, E. Espinosa, A. M.Alonso, P. Cejas, D. 
Hardisson, J.A.F. Vara, C. Belda-Iniesta, M. González-Barón, and J. M.Cuezva, Breast 
Carcinomas Fulfill the Warburg Hypothesis and Provide Metabolic Markers of Cancer 
Prognosis. Carcinogenesis (2005), 26: 2095-2104 
51. Isidoro, A., E. Casado, A. Redondo, P. Acebo, E. Espinosa, A.M. Alonso, P. Cejas, D. 
Hardisson, J.A. Fresno Vara, C. Belda-Iniesta, M. González-Barón, and J.M. Cuezva, 
Breast Carcinomas Fulfill the Warburg Hypothesis and Provide Metabolic Markers of 
Cancer Prognosis. Carcinogenesis (2005), 26(12): 2095-2104 
52. International Agency for Research on Cancer, World Health Organization, Chromium, 
Nickel and Welding. IARC Monographs on the Evaluation of Carcinogenic Risks to 
Humans (1990), 49: 49-256 
53. Barceloux, D.G., Chromium. Clin Toxicol (1999), 37(2): 173-194 
54. O’Brien, T.J., S. Ceryak, and S.R. Patierno, Complexities of Chromium Carcinogenesis: 
Role of Cellular Response, Repair and Recovery Mechanisms. Mutat Res (2003), 533 3–36 
55. Manahan, S.E., Toxicological Chemistry and Biochemistry (2003), 3rd Edition, Lewis 
Publishers a CRC Press Company, Florida 
56. Roat-Malone, R.M., Bioinorganic Chemistry: a Short Course (2002), John Wiley & Sons, 
Inc., New Jersey 
57. Cotton, F.A., G.Wilkinson, C.A. Murillo, and M. Bochmann, Advanced Inorganic 
Chemistry (1999), 6th Edition, John Wiley & Sons, Inc, New York 
58. Antonini, J.M., M.D. Taylor, A.T. Zimmer, and J.R. Roberts, Pulmonary Responses to 
Welding Fumes: Role of Metal Constituents. J Toxicol Environ Health A (2003), 67: 233-
249 
59. Agency for Toxic Substances and Disease Registry, Toxicological Profile for Chromium - 
Draft for Public Comment. U.S. Department of Health and Human Services (2008), 7440-
47-3 
60. Tsuneta, Y., Y. Ohsaki, K. Kimura, H. Mikami, S. Abe, and M. Murao, Chromium Content 
of Lungs of Chromate Workers with Lung Cancer. Thorax (1980), 35: 294-297 
61. Raithel, H.-J., K.-H. Schaller, T. Kraus, and G. Lehnert, Biomonitoring of Nickel and 
Chromium in Human Pulmonary Tissue. Int Arch Occup Environ Health (1993), 65: 5197-
5200 
62. Balk, E.M., A. Tatsioni, A.H. Lichtenstein, M. Joseph Lau, and A.G. Pittas, Effect of 
Chromium Supplementation on Glucose Metabolism and Lipids. Diabetes Care (2007), 
30(8): 2154-2163 
63. Urbano, A.M., C.F.D. Rodrigues, and M.C. Alpoim, Hexavalent Chromium Exposure, 
Genomic Instability and Lung Cancer. Gene Ther Mol Biol (2008), 12: 219-238 
64. Kotas, J. and Z. Stasicka, Chromium Occurrence in the Environment and Methods of its 
Speciation. Environ Pollut (2000), 107(3): 263-283 
References 
 
 
50 
 
65. De Flora, S., A. Camoirano, M. Bagnasco, C. Bennicelli, G.E. Corbett, and B.D. Kerger, 
Estimates of the Chromium(VI) Reducing Capacity in Human Body Compartments as a 
Mechanism for Attenuating its Potential Toxicity and Carcinogenicity. Carcinogenesis 
(1997), 18(3): 531-537 
66. Costa, M., Potential Hazards of Hexavalent Chromate in our Drinking Water. Toxicol Appl 
Pharmacol (2003), 188: 1-5 
67. Alexander, J. and J. Aaseth, Uptake of Chromate in Human Red Blood Cells and Isolated 
Rat Liver Cells: The Role of the Anion Carrier. Analyst (1995), 120: 931-933 
68. Levina, A. and P.A. Lay, Mechanistic Studies of Relevance to the Biological Activities of 
Chromium. Coord Chem Rev (2005), 249(3-4): 281-298 
69. Ishikawa, Y., K. Nakagawa, Y. Sato, T. Kitagawa, H. Sugano, T. Hirano, and E. Tsuchiya, 
Characteristics of Chromate Workers' Cancers, Chromium Lung Deposition and 
Precancerous Bronchial Lesions: an Autopsy Study. Br J Cancer (1994), 70: 160-166 
70. Kondo, K., Y. Takahashi, S. Ishikawa, H. Uchihara, Y. Hirose, K. Yoshizawa, M. Tsuyuguchi, 
H. Takizawa, T. Miyoshi, S. Sakiyama, and Y. Monden, Microscopic Analysis of Chromium 
Accumulation in the Bronchi and Lung of Chromate Workers. Cancer (2003), 98(11): 
2420-2429 
71. Halasova, E., T. Matakova, E. Kavcova, L. Musak, L. Letkova, M. Adamkov, M. Ondrusova, 
E. Bukovska, and A. Singliar, Human Lung Cancer and Hexavalent Chromium Exposure 
(2009). Vol. 30, Society of Integrated Sciences 
72. Slade, R., Stead, A. G., Graham, J. A., Hatch, and G. E., Comparison of Lung Antioxidant 
Levels in Humans and Laboratory Animals (1985). Vol. 131, American Lung Association, 
New York 
73. Stearns, D.M. and K.E. Wetterhahn, Reaction of Chromium(VI) with Ascorbate Produces 
Chromium(V), Chromium(IV), and Carbon-Based Radicals. Chem Res Toxicol (1994), 7: 
219-230 
74. Standeven, A.M. and K.E. Wetterhahn, Ascorbate is the Principal Reductant of 
Chromium(VI) in Rat Liver and Kidney Ultrafiltrates. Carcinogenesis (1991), 12(9): 1733-
1737 
75. Zhitkovich, A., G. Quievryn, J. Messer, and Z. Motylevich, Reductive Activation with 
Cysteine Represents a Chromium(III)-Dependent Pathway in the Induction of Genotoxicity 
by Carcinogenic Chromium(VI). Environ Health Perspect (2002), 110(5): 729-731 
76. Sugden, K.D. and K.E. Wetterhahn, Direct and Hydrogen Peroxide-Induced Chromium(V) 
Oxidation of Deoxyribose in Single-Stranded and Double-Stranded Calf Thymus DNA. 
Chem Res Toxicol (1997), 10(12): 1397-1406 
77. Slade, P.G., M.K. Hailer, B.D. Martin, and K.D. Sugden, Guanine-Specific Oxidation of 
Double-Stranded DNA by Cr(VI) and Ascorbic Acid Forms Spiroiminodihydantoin and 8-
oxo-2'-Deoxyguanosine. Chem Res Toxicol (2005), 18(7): 1140-1149 
78. Casadevall, M., P. da Cruz Fresco, and A. Kortenkamp, Chromium(VI)-Mediated DNA 
Damage: Oxidative Pathways Resulting in the Formation of DNA Breaks and Abasic Sites. 
Chem Biol Interact (1999), 123(2): 117-132 
79. Zhitkovich, A., Importance of Chromium-DNA Adducts in Mutagenicity and Toxicity of 
Chromium(VI). Chem Res Toxicol (2005), 18(1): 3-11 
References 
 
 
51 
 
80. Molyneux, M.J. and M.J. Davies, Direct Evidence for Hydroxyl Radical-Induced Damage to 
Nucleic Acids by Chromium(VI)-Derived Species: Implications for Chromium 
Carcinogenesis. Carcinogenesis (1995), 16(4): 875-882 
81. Hojo, Y., K. Nishiguchi, S. Kawazoe, and T. Mizutani, Comparision of Susceptibility of Liver 
and Kidney to Lipid Peroxidation Induction by Cr(IV), Cr(V) and Cr(VI) Compounds. J 
Health Sci (1999), 6: 329-332 
82. Chen, F., J. Ye, X. Zhang, Y. Rojanasakul, and X. Shi, One-Electron Reduction of 
Chromium(VI) by a-Lipoic Acid and Related Hydroxyl Radical Generation, dG 
Hydroxylation and Nuclear Transcription Factor-kB Activation. Arch Biochem Biophys 
(1997), 338(2): 165-172 
83. O'Hara, K.A., L.R. Klei, and A. Barchowsky, Selective Activation of Src Family Kinases and 
JNK by Low Levels of Chromium(VI). Toxicol Appl Pharmacol (2003), 190(3): 214-223 
84. Rudolf, E., M. Cervinka, J. Cerman, and L. Schroterova, Hexavalent Chromium Disrupts 
the Actin Cytoskeleton and Induces Mitochondria-Dependent Apoptosis in Human 
Dermal Fibroblasts. Toxicol In Vitro (2005), 19(6): 713-723 
85. Costa, A.N., V. Moreno, M.J. Prieto, A.M. Urbano, and M.C. Alpoim, Induction of 
Morphological Changes in BEAS-2B Human Bronchial Epithelial Cells Following Chronic 
Sub-Cytotoxic and Mildly Cytotoxic Hexavalent Chromium Exposures. Mol Carcinog 
(2010), 49(6): 582-591 
86. Hodges, N.J., B. Ádám, A.J. Lee, H.J. Cross, and J.K. Chipman, Induction of DNA-Strand 
Breaks in Human Peripheral Blood Lymphocytes and A549 Lung Cells by Sodium 
Dichromate: Association with 8-Oxo-2-Deoxyguanosine Formation and Inter-Individual 
Variability. Mutagenesis (2001), 16(6): 467-474 
87. El-Demerdash, F.M., M.I. Yousef, and F.A.M. Elaswad, Biochemical Study on the 
Protective Role of Folic Acid in Rabbits Treated with Chromium (VI). J Environ Sci Health B 
(2006), 41(5): 731 - 746 
88. Beaver, L.M., E.J. Stemmy, A.M. Schwartz, J.M. Damsker, S.L. Constant, S.M. Ceryak, and 
S.R. Patierno, Lung Inflammation, Injury, and Proliferative Response after Repetitive 
Particulate Hexavalent Chromium Exposure. Environ Health Perspect (2009), 117(12) 
89. Xu, J., G.J. Bubley, B. Detrick, L.J. Blankenship, and S.R. Patierno, Chromium(VI) 
treatment of normal human lung cells results in guanine-specific DNA polymerase arrest, 
DNA-DNA cross-links and S-phase blockade of cell cycle. Carcinogenesis (1996), 17(7): 
1511-1517 
90. Asatiani, N., N. Sapojnikova, M. Abuladze, T. Kartvelishvili, N. Kulikova, E. Kiziria, E. 
Namchevadze, and H.-Y. Holman, Effects of Cr(VI) Long-Term and Low-Dose Action on 
Mammalian Antioxidant Enzymes (an in Vitro Study). J Inorg Biochem (2004), 98(3): 490-
496 
91. Holmes, A.L., S.S. Wise, S.J. Sandwick, and J.P. Wise Sr, The Clastogenic Effects of Chronic 
Exposure to Particulate and Soluble Cr(VI) in Human Lung Cells. Mutat Res (2006), 610(1-
2): 8-13 
92. Bianchi, V., P. Debetto, A. Zantedeschi, and A.G. Levis, Effects of Hexavalent Chromium 
on the Adenylate Pool of Hamster Fibroblasts. Toxicology (1982), 25(1): 19-30 
93. Ryberg, D. and J. Alexander, Inhibitory Action of Hexavalent Chromium (Cr(VI)) on the 
Mitochondrial Respiration and a Possible Coupling to the Reduction of Cr(VI). Biochem 
Pharmacol (1984), 33(15): 2461-2466 
References 
 
 
52 
 
94. Fernandes, M.A.S., M.S. Santos, M.C. Alpoim, V.M.C. Madeira, and J.A.F. Vicente, 
Chromium(VI) Interaction with Plant and Animal Mitochondrial Bioenergetics: A 
Comparative Study. J Biochem Mol Toxicol (2002), 16(2): 53-63 
95. Debetto, P. and S. Luciani, Toxic Effect of Chromium on Cellular Metabolism. Sci Total 
Environ (1988), 71(3): 365-377 
96. Gonçalves, M.J., A.C.C. Santos, C.F.D. Rodrigues, P. Coelho, A.N. Costa, A.J. Guiomar, 
M.S. Santos, M.C. Alpoim, and A.M. Urbano, Changes in Glucose Uptake Rate and in the 
Energy Status of PC-12 Cells Acutely Exposed to Hexavalent Chromium, an Established 
Human Carcinogen. Toxicol Environ Chem (2011), 93(6) 
97. Myers, C.R., W.E. Antholine, and J.M. Myers, The Pro-Oxidant Chromium(VI) Inhibits 
Mitochondrial Complex I, Complex II, and Aconitase in the Bronchial Epithelium: EPR 
Markers for Fe-S Proteins. Free Radical Biology and Medicine (2010), 49(12): 1903-1915 
98. Myers, J.M., W.E. Antholine, and C.R. Myers, Hexavalent Chromium Causes the Oxidation 
of Thioredoxin in Human Bronchial Epithelial Cells. Toxicology (2008), 246(2-3): 222–233 
99. Myers, J.M. and C.R. Myers, The Effects of Hexavalent Chromium on Thioredoxin 
Reductase and Peroxiredoxins in Human Bronchial Epithelial Cells. Free Radic Biol Med 
(2009), 47(10): 1477-1485 
100. Reddel, R.R., Y. Ke, B.I. Gerwin, M.G. McMenamin, J.F. Lechner, R.T. Su, D.E. Brash, J.-B. 
Park, J.S. Rhim, and C.C. Harris, Transformation of Human Bronchial Epithelial Cells by 
Infection with SV40 or Adenovirus-12 SV40 Hybrid Virus, or Transfection via Strontium 
Phosphate Coprecipitation with a Plasmid Containing SV40 Early Region Genes. Cancer 
Research (1988), 48(7): 1904-1909 
101. DeCaprio, J.A., J.W. Ludlow, J. Figge, J.-Y. Shew, C.-M. Huang, W.-H. Lee, E. Marsilio, E. 
Paucha, and D.M. Livingston, SV40 Large Tumor Antigen Forms a Specific Complex with 
the Product of the Retinoblastoma Susceptibility Gene. Cell (1988), 54(2): 275-283 
102. Finlay, C.A., P.W. Hinds, and A.J. Levine, The p53 Proto-Oncogene Can Act as a 
Suppressor of Transformation. Cell (1989), 57(7): 1083-1093 
103. Ke, Y., R.R. Reddel, B.I. Gerwin, M. Miyashita, M. McMenamin, J.F. Lechner, and C.C. 
Harris, Human Bronchial Epithelial Cells with Integrated SV40 virus T Antigen Genes 
Retain the Ability to Undergo Squamous Differentiation. Differentiation (1988), 38(1): 
60-66 
104. Singh, J., D.E. Pritchard, D.L. Carlisle, J.A. McLean, A. Montaser, J.M. Orenstein, and S.R. 
Patierno, Internalization of Carcinogenic Lead Chromate Particles by Cultured Normal 
Human Lung Epithelial Cells: Formation of Intracellular Lead-Inclusion Bodies and 
Induction of Apoptosis. Toxicol Appl Pharmacol (1999), 161(3): 240-248 
105. Caglieri, A., M. Goldoni, G.D. Palma, P. Mozzoni, S. Gemma, S. Vichi, E. Testai, F. Panico, 
M. Corradi, S. Tagliaferri, and L.G. Costa, Exposure to Low Levels of Hexavalent 
Chromium: Target Doses and Comparative Effects on Two Human Pulmonary Cell Lines. 
Acta Biomed (2008), 79(1): 104-115  
106. Wakeman, T., D. Wyczechowska, and B. Xu, Involvement of the p38 MAP Kinase in Cr(VI)-
Induced Growth Arrest and Apoptosis. Mol Cell Biochem (2005), 279(1): 69-73 
107. Gao, N., B.-H. Jiang, S.S. Leonard, L. Corum, Z. Zhang, J.R. Roberts, J. Antonini, J.Z. Zheng, 
D.C. Flynn, V. Castranova, and X. Shi, p38 Signaling-Mediated Hypoxia-Inducible Factor 
1a and Vascular Endothelial Growth Factor Induction by Cr(VI) in DU145 Human Prostate 
Carcinoma Cells. J Biol Chem (2002), 277(47): 45041-45048 
References 
 
 
53 
 
108. Zhang, Z., S.S. Leonard, S. Wang, V. Vallyathan, V. Castranova, and X. Shi, Cr(VI) Induces 
Cell Growth Arrest Through Hydrogen Peroxide-Mediated Reactions. Mol Cell Biochem 
(2001), 222(1): 77-83 
109. Bianchi, V., A.G. Levis, and D. Saggioro, Differential Cytotoxic Activity of Potassium 
Dichromate on Nucleoside Uptake in BHK Fibroblasts. Chem Biol Interact (1979), 24(2): 
137-151 
110. Borthiry, G.R., W.E. Antholine, J.M. Myers, and C.R. Myers, Reductive Activation of 
Hexavalent Chromium by Human Lung Epithelial Cells: Generation of Cr(V) and Cr(V)-
Thiol Species. J Inorg Biochem (2008), 102(7): 1449-1462 
111. Karaczyn, A., S. Ivanov, M. Reynolds, A. Zhitkovich, K.S. Kasprzak, and K. Salnikow, 
Ascorbate Depletion Mediates Up-Regulation of Hypoxia-Associated Proteins by Cell 
Density and Nickel. J Cell Biochem (2006), 97(5): 1025-1035 
112. Snow, E.T. and L.S. Xu, Chromium(III) Bound to DNA Templates Promotes Increased 
Polymerase Processivity and Decreased Fidelity During Replication in Vitro. Biochemistry 
(1991), 30(47): 11238-11245 
113. Bridgewater, L. C., Manning, F.C. R., Woo, E. S., Patierno, and S. R., DNA Polymerase 
Arrest by Adducted Trivalent Chromium (1994). Vol. 9, Wiley-Liss, New York 
114. Rodrigues, C.F.D., A.M. Urbano, E. Matoso, I. Carreira, A. Almeida, P. Santos, F. Botelho, 
L. Carvalho, M. Alves, C. Monteiro, A.N. Costa, V. Moreno, and M.C. Alpoim, Human 
Bronchial Epithelial Cells Malignantly Transformed by Hexavalent Chromium Exhibit an 
Aneuploid Phenotype but no Microsatellite Instability. Mutat Res (2009), 670: 42-52 
115. ECCAC - European Collection of Cell Cultures, General Cell Collection: BEAS-2B, Health 
Protection Agency Culture Collection, Cat. No.: 95102433 
116. Lechner, J.F. and M.A. LaVeck, A Serum-Free Method For Culturing Normal Human 
Bronchial Epithelial Cells At Clonal Density. J Tissue Cult Methods Vol (1985), 9(2): 43-48 
117. Peehl, D.M. and R.G. Ham, Clonal Growth Of Human Keratinocytes With Small Amounts 
Of Dialyzed Serum. In Vitro (1980), 16(6): 526-538 
118. Iype, P.T., G.D. Stoner, B.W. Gabriel, and M.E. Kaighn, A Serum-Free Medium For Human 
Epidermal-Like Cells. In Vitro Cell (1993), 29A: 94-96 
119. Franken, N.A.P., H.M. Rodermond, J. Stap, J. Haveman, and C.v. Bree, Clonogenic Assay 
of Cells in Vitro. Nat Protoc (2006), 1(5): 2315-2319 
120. Bio-Rad, Bio-Rad Protein Assay, Cat. No.: 1-800-424-6723 
121. seahorsebio.com. XF Products: How XF Analyzers Work (assessed date: May 2011) 
122. Ferrick, D.A., A. Neilson, and C. Beeson, Advances in Measuring Cellular Bioenergetics 
Using Extracellular Flux. Drug Discov Today (2008), 13(5/6): 268-274 
123. Deluca, M., W.D. McElroy, and A.D. Marlene, Purification and Properties of Firefly 
Luciferase, in Methods in Enzymology. Academic Press (1978), 57: 3-15 
124. Laemmli, U.K., Cleavage of Structural Proteins During the Assembly of the Head of 
Bacteriophage T4. Nature (1970), 227(259): 680-685 
125. Armstrong, D., E. Eruslanov, and S. Kusmartsev, Identification of ROS Using Oxidized 
DCFDA and Flow-Cytometry, in Advanced Protocols in Oxidative Stress II. Humana Press 
(2010), 594: 57-72 
126. Millipore, OxyBlot™ Protein Oxidation Detection Kit, Cat. No.: S7150 
References 
 
 
54 
 
127. Wu, M., A. Neilson, A.L. Swift, R. Moran, J. Tamagnine, D. Parslow, S. Armistead, K. 
Lemire, J. Orrell, J. Teich, S. Chomicz, and D.A. Ferrick, Multiparameter Metabolic 
Analysis Reveals a Close Link Between Attenuated Mitochondrial Bioenergetic Function 
and Enhanced Glycolysis Dependency in Human Tumor Cells. American Journal of 
Physiology - Cell Physiology (2007), 292(1): C125-C136 
128. Moran, M., H. Rivera, M. Sánchez-Aragó, A. Blazquez, B. Merinero, C. Ugalde, J. Arenas, 
J.M. Cuezva, and M.A. Martin, Mitochondrial Bioenergetics and Dynamics Interplay in 
Complex I-Deficient Fibroblasts. Biochim Biophys Acta (2010), 1802(5): 443-453 
129. Davies, K.J., Protein Damage and Degradation by Oxygen Radicals. I. General Aspects. J 
Biol Chem (1987), 262(20): 9895-9901 
130. Debetto, P., R.D. Toso, R. Varotto, V. Bianchi, and S. Luciani, Effects of Potassium 
Dichromate on ATP Content of Mammalian Cells Cultured in Vitro. Chem Biol Interact 
(1982), 41(1): 15-24 
131. Gardner, P.R., D.D. Nguyen, and C.W. White, Aconitase is a Sensitive and Critical Target 
of Oxygen Poisoning in Cultured Mammalian Cells and in Rat Lungs. Proc Natl Acad Sci U 
S A (1994), 91(25): 12248-12252 
132. Sánchez-Cenizo, L., L. Formentini, M. Aldea, Á.D. Ortega, P. García-Huerta, M. Sánchez-
Aragó, and J.M. Cuezva, Up-Regulation of the ATPase Inhibitory Factor 1 (IF1) of the 
Mitochondrial H+-ATP Synthase in Human Tumors Mediates the Metabolic Shift of Cancer 
Cells to a Warburg Phenotype. Journal of Biological Chemistry 285(33): 25308-25313 
 
  
 
 
 
 
 
 
 
 
 
Supplemental Material  
 
Supplemental Material 
 
 
 
 
1) Composition of Solutions Commonly used During the 
Experimental Procedures 
 
All reagents and solvents used in the practical work were from analytical grade. All 
aqueous solutions were prepared with distilled water treated in a Milli-Q water purification 
system, unless specified. All aqueous solutions and material used in asepsis conditions, which 
were not bought sterilized, were sterilized either by moist heat sterilization for 22 minutes at 
121 oC (when suitable) or by syringe with 0.2 µm filters pores. 
 
1.1) Composition of Solutions used in Tissue Culture and Clonogenic 
Assay 
1) 10x PBS 
- 14.7 mM KH
2
PO
4
 
- 81.0 mM Na
2
HPO
4
 
- 1370.0 mM NaCl 
- 26.8 mM KCl in water.  
The pH of this solution was adjusted to pH 7.4 with 1.0 M NaOH or 1.0 M HCl solutions 
and stored at room temperature. 
1x PBS solution was prepared from 10x PBS by adding the appropriate volume of water. 
This solution was subjected to moist heat sterilization and stored at 4 oC. 
 
2) 1 M NaOH  
- Prepared by dissolving an appropriate amount of NaOH in water. 
This solution was stored at room temperature. 
 
3) 1 M HCl  
- Prepared by diluting a 37% HCl solution with water. 
This solution was stored at room temperature. 
 
4) 2% (w/v) Gelatin  
- Prepared by dissolving an appropriate amount of gelatin from bovine skin - type B 
in water. 
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This solution was subjected to moist heat sterilization and stored at 4 oC. 
 
5) 2% (w/v) BSA 
- Prepared by dissolving an appropriate amount of BSA in water. 
This solution was sterilized using a 0.2 µm pore size filter and stored at 4 oC. 
 
6) Coating – solution 
- Prepared with 2% gelatin, 1x PBS and 2% BSA in the proportions of 50%, 45% and 
5%, respectively. 
This solution was prepared with sterile solutions and stored at 4 oC. 
 
7) 1x Trypsin 
- Prepared by diluting a 10x trypsin stock solution from porcine pancreas (25 g/L in 
0.9% sodium chloride) with 1x PBS.   
This solution was prepared with sterile solutions and stored at 4 oC. 
 
8) 1 mM Cr(VI) solution  
- Prepared by dissolving an appropriate amount of K2Cr2O7 in water. 
This solution was stored at room temperature. 100 µM and 10 µM solutions were 
prepared by dilution of the stock solution with water. Both solutions were sterilized using a 0.2 
µm pore size filter and stored at 4 oC. 
 
9) Colony fixation-staining solution 
-  6.0% (v/v) glutaraldehyde  
-  0.5% (w/v) crystal violet in water. 
This solution was stored at 4 oC. 
1.2) Composition of Solutions used in SDS-PAGE and Western Blot 
1) 5x buffer 
- 1 M Tris base, pH 6.8: 25% 
- 2-Mercaptoethanol: 25% 
- 85% (v/v) Glycerol: 50%. 
For  1 mL of solution, 0.1 g of sodium dodecyl sulfate (SDS) and 0.005 g of bromophenol 
blue sodium salt was added.  
The solution was aliquoted and stored at -20 oC.  
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2) Running and stacking gels 
9% Running gels were prepared by adding, in the order given, the following 
components:  
- Water (1.83 mL) 
- 40% (v/v) Acrylamide/bis solution (1.13 mL)  
- Tris base solution (pH 8.8) (1.95 mL) 
- 10% (w/v) SDS (0.05 mL) 
- 10% (w/v) Ammonium persulfate (0.05 mL)  
- N,N,N',N'-Tetramethylethylenediamine (TEMED) (0.003 mL). 
 
5% Stacking gels were prepared by adding, in the order given, the following 
components: 
- Water (2.19 mL) 
- 40% (v/v) Acrylamide/bis solution (0.37 mL)  
- Tris base solution (pH 6.8) (0.38 mL) 
- 10% (w/v) SDS (0.03 mL) 
- 10% (w/v) Ammonium persulfate (0.03 mL)  
- TEMED (0.003 mL). 
 
3) Electrophoresis buffer 
- 150 mM Tris base 
- 192 mM Glycine 
- 3.4 mM SDS in water. 
This solution was stored at room temperature. 
 
4) Electrotransference buffer 
The solution was prepared, just before use, by dilution of a 10x stock solution (1:10) in 
water and methanol. The final solution contained: 
- 1x electrotransference buffer 
o 48 mM tris base 
o 39 mM glycine  
- 20% (v/v) methanol. 
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5) Tris buffered saline – tween 20 (TBS-T) buffer 
The solution was prepared, just before use, by dilution of a 10x TBS stock solution (pH 
7.4) in water (1:10) and addition of tween 20. The final solution contained: 
- 1x TBS: 
o 150 mM NaCl  
o 50 mM Tris base 
- 0.1% (v/v) Tween 20.  
 
6) Membrane block solution 
- 5% (w/v) Nonfat dry milk diluted in TBS-T. 
The solution was prepared just before used. 
 
7) Primary antibodies dilute solution 
- 3% BSA in a 0.002 M sodium azide solution. 
This solution was prepared in aliquots and stored at -20 oC.  
The diluted primary antibody solution was stored a 4 oC. 
 
1.3) Composition of Solutions used in Lactate Levels Assessment 
1) Lactate buffer 
- 1.0 M Glycine 
- 0.4 M Hydrazine hydrate 
- 1.3 M EDTA. 
The pH of this solution was adjusted to 9.5 with a NaOH solution and prepared just 
before use.   
 
2) 6% (v/v) Perchloric acid  
- Prepared by dilution of a 60% (v/v) perchloric acid solution. 
This solution was stored at room temperature. 
 
3) 20% (w/v) KOH  
- Prepared by dissolving an appropriate amount of KOH in water. 
This solution was stored at room temperature. 
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1.4) Composition of Solutions used to Prepare Protein Extracts  
1) Protein lysis buffer 
- 1.0 M Tris base (pH 8): 0.025 mL 
- 0.5 M EDTA: 0,200 mL 
- 10% (v/v) Triton X-100: 0.250 mL. 
For a final volume of 0.475 mL half tablet of EDTA-free protease inhibitor was added. 
This solution was stored at -20 oC in aliquots. 
 
1.5) Composition of Solutions used to Determine ATP Levels 
1) ATP lysis buffer 
- 100 mM Tris base 
- 4 mM EDTA. 
The pH of the solution was adjusted to 7.75 and stored at room temperature. 
 
1.6) Composition of Solutions used to Determine Radical Species Levels 
1) 5 µM DCFH-DA 
- A 10 mM DCFH-DA solution was diluted with 1x PBS. 
The stock solution was stored at -70 oC in aliquots and the 5 µM solution was 
prepared just before use. The recipient was protected from light with aluminum.    
 
1) FACS solution 
- 1.0% FBS 
- 0.1 % Sodium azide in 1x PBS. 
This solution was stored at 4 oC.  
 
 
2) Suppliers  
 
2.1) Reagents and Solutions 
1) Sigma-Aldrich, St. Louis, USA, provided:  
- 0.4% (m/v) Trypan blue solution (T8154) to count cells; 
- DNP to treat cells; 
- 2-DG (D3179) to treat cells; 
- Antimycin A (A8674) to treat cells; 
Supplemental Material 
 
 
 
 
- Dimethyl sulfoxide (D589) to froze cells;  
- Dithiothreitol (D9779) to use as a reducing agent; 
- EDTA (ED2SS) to prepare multiple solutions;  
- Gelatin from bovine skin - type B (G9391) and bovine serum albumin (A9418) to coat 
culture flasks; 
- Glutaraldehyde solution (G5882) and crystal violet (C3886) to prepare colony fixation-
staining solutions; 
- Hydrazine hydrate (225819) to prepare lactate buffer; 
- K2Cr2O7 (P2588) to prepare Cr(VI) solutions; 
- KH2PO4 (P5379), NaCl (S9625), Na2HPO4 (S0876-500G) and KCl (P5405) to prepare 10x 
PBS; 
- Methanol (32213) to prepare western blot solutions;  
- OL (O4876) to treat cells;  
- PI(P4170) to detect dead cells; 
- Rotenone (R8875) to treat cells; 
- SDS (L5750) to prepare multiple solutions; 
- Sodium azide (S2002) to prepare multiple solutions;  
- Tris base (T1503) to prepare multiple solutions; 
- Trypsin solution from porcine pancreas (T8154) to use in the culture cells routine; 
- Tubulin antibody (monoclonal, T5168) to use on western blot procedures; 
- NAD+ (N1511) to use on lactate measurements;  
 
2) Merck Chemicals, Darmstadt, DE, provided: 
- 2-Mercaptoethanol (8.05740.0250) and 85% glycerol (1.04094.1000) to prepare 5x 
buffer; 
- 60% Percloric acid (1.00518.1001) to prepare 6% percloric acid solutions to use on 
lactate measurements; 
- Bromophenol blue sodium salt (111746) to prepare 5x buffer; 
- Glycine (5.00190.1000) to prepare western blot solutions and lactate buffer;  
- pH-indicator solution-pH 4 -10 (1.09175.0100) to monitor the pH of solutions; 
- NaOH (6498.1000) to prepare the 20% NaOH solution to use on lactate measurements;  
- Triton X-100 (1.12298.0101) to prepare protein lysis buffer; 
- TWEEN® 20 – detergent (655205) to prepare western blot solutions; 
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3)  Invitrogen, Barcelona, ES,  provided: 
- FBS (10106-169) to froze cells; 
- LHC-9 medium (12680-013) to use in culture cells’ routine; 
- Novex® ECL chemiluminescent reagent kit (WP20005) to reveal immunoblots; 
- DCFH-DA (D-399) to detect radical species formation; 
 
4) Panreac Química, S.A., Barcelona, ES, provided: 
- HCl (131020.0719) to prepare pH adjustment solutions; 
 
5) Bio-Rad, Madrid, ES, provided: 
- 40% Acrylamide/Bis Solution 29:1 to (161-0146) to use on western blot procedures; 
- Ammonium persulfate (161-0700) to use on western blot procedures; 
- Bio-Rad's protein assay kit (500-0006) to determine protein concentrations by Bradford 
method; 
- TEMED (161-0801) to use on western blot procedures; 
 
6) Roche, Madrid, ES, provided: 
- ATP bioluminescence assay kit HS II (11 699 709 001) to determine ATP levels;  
- EDTA-free protease inhibitor cocktail tablets (11 836 170 001) to prepare protein lysis 
buffer;  
- LDH (10 127 230 001) to determine lactate levels on medium samples; 
 
7) GE Healthcare, Barcelona, ES, provided: 
- Amersham full-range rainbow molecular weight markers (RPN800E) to use on western 
blot procedures;  
 
8) Abcam, Cambridge, UK, provided: 
- GAPDH antibody (ab8245) to use on western blot procedures; 
 
9) Enzo Life Sciences, Madrid, ES, provided: 
- Hsp60 antibody (ADI-SPA-807-E) to use on western blot procedures; 
 
10) Nordic Immunology, Madrid, ES provided: 
- Peroxidase-conjugated anti-mouse (5541) or anti-rabbit secondary (6105) antibodies;  
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11) Seahorse Bioscience, Copenhagen, DK, provided: 
- Calibration solution (100840-000) to place into the XF 24-well analyzer microplates; 
 
12) Millipore, Madrid, ES, provided: 
- OxyBlot protein oxidation detection kit (S7150) to detect the levels of carbonylation of 
proteins;  
 
 
2.2) Material and Equipment: 
1) Nalgene, New York, USA, provided: 
- Mr Frosty cryo 1 oC freezing container to froze cells; 
 
2) Corning, New York, USA, provided: 
- Flasks with vented cap and test plates to tissue culture handling; 
 
3) Orange Scientific, Braine-l'Alleud, BE, provided: 
- Falcon tubes to tissue culture handling and to aqueous solutions storage; 
- Flasks with vented cap and test plates to tissue culture handling; 
 
4) BD Falcon, Madrid, ES, provided: 
- Falcon tubes to tissue culture handling and to aqueous solutions storage; 
- Petri dishes (multiple sizes) to tissue culture handling; 
- Serologic pipettes to  tissue culture handling; 
 
5) Sarstedt, Rio de Mouro, PT, provided: 
- Falcon tubes to tissue culture handling and to aqueous solutions storage; 
- Serologic pipettes to  tissue culture handling; 
 
6) Prestige Medical, Blackburn, UK, provided: 
- Omega autoclave to perform heat moist sterilizations; 
 
7)  Millipore, S.A., Molsheim, FR, provided: 
- SimplicityTM  Milli-Q water purification system; 
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8) Bio-Rad, Madrid, ES, provided: 
- Mini-PROTEAN 3® system to perform SDS-PAGE; 
- Trans-Blot® Electrophoretic Transfer Cell to perform protein electrotransference; 
 
9) KOJAIR, Vilppula, FI, provided: 
- Biowizard – 100 class II safety cabinet to tissue culture handling in aseptic conditions; 
 
10) Kodak, Madrid, ES, provided: 
- Kodak-X-OMAT 2000 processor to image processing; 
 
11) Seahorse Bioscience, Copenhagen, DK, provided: 
- Seahorse XF24 Analyzer to determine OCR; 
- XF 24-well tissue culture microplates to seed the cells for OCR determinations;  
- XF 24-well XF24 analyzer microplates containing the sensors cartridges and the drug 
delivery system to determine OCR; 
 
12) Cultek, Madrid, ES, provided: 
- Cultair BC 100 safety cabinet to tissue culture handling in aseptic conditions; 
 
13) Thermo Scientific, Aalst, BE, provided: 
- Microcentrifuge, model micro CL 17R, to centrifuge samples contained in eppendorfs; 
- Steri-cycle CO2 incubator Hepa class 100, model 371, to maintain tissue cultures at 37 
oC 
with 5% (v/v) CO2 in air;  
 
14) Hettich Zentrifugen, Madrid, ES, provided: 
- Centrifuge, model Rotanta 460 R, to centrifuge samples contained in falcons; 
 
15) MPW Med. Instruments, Warsaw, PL, provided: 
- Centrifuge, model MPW-350R, to centrifuge samples contained in falcons; 
 
16) Sheldon Manufacturing Inc., Cornelius, US: 
- Water jacket CO2 incubator, model 3517-2, to maintain tissue cultures at 37 
oC with 5% 
(v/v) CO2 in air;  
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17) Olympus, Lisbon, PT, provided: 
- Digital camera integrated into the CKX41 microscope, model DP 20-5E, to take pictures 
to tissue cultures;  
- Inverted microscope, model CKX41, to tissue culture visualization; 
 
18) Leica Microsystems, Barcelona, ES, provided: 
- Inverted microscope, model DM IL LED, to tissue culture visualization. 
 
19) Clifton, provided: 
- Thermoestatic  water bath, model NE1B-14, to warm solution for tissue culture 
handling; 
 
20) Hanna Instruments, Póvoa de Varzim, PT, provided: 
- Benchtop pH meter, model HI 110, to adjust the pH of aqueous solutions; 
 
21) Sartorius, Goettingen, DE, provided: 
- Analytical balance, model  ALC-810.2 (from the extinct brand Acculab), to prepare 
multiple solutions; 
- Precision balance, model ED3202S, to prepare multiple solutions; 
 
22) Mettler Toledo, Barcelona, ES, provided: 
- Analytical balance, model AE 50, to prepare multiple solutions; 
 
23) Eppendorf, Madrid, ES, provided: 
- Adjustable-volume automatic pipettes, model Eppendorf Research with the references 
3111 000.130, 3111 000.157 and 3111 000.165, to use in routinely laboratory tasks; 
 
24) Gilson, Madrid, ES, provided:  
- Adjustable-volume automatic pipettes, model PIPETMAN Classic with the references 
F144801, F144802, F123600, F123601 and  F123602 to use in routinely laboratory tasks; 
 
25) BMG Labtech, Madrid, ES, provided: 
- Microplate reader, model FLUOstar OPTIMA, to detect luminescence; 
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26) BD Bioscience, Madrid, ES, provided: 
- Flow cytometer, model BD FACSCalibur, to detect reactive oxygen species;  
 
 
